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2 CHAPTER 1
Introduction
The presence of diabetic nephropathy determines to a great extent the prognosis
of patients with type 1 diabetes mellitus. In the Netherlands diabetic nephropathy
is a major cause of end-stage renal disease (prevalence about 14-16%). Besides
end-stage renal disease, the presence of diabetic nephropathy is also a strong
prognostic factor for the development of cardiovascular morbidity and mortality.
Historical data show that about 20-40% of type 1 diabetes mellitus patients will
finally develop diabetic nephropathy.
Earlier studies, like the Diabetes Control and Complications Trial (DCCT),
have clearly shown that improved glycaemic control reduces the development of
diabetic complications. Besides, treatment of hypertension improves the degree
of albuminuria, and slows the deterioration of glomerular filtration rate. A recent
meta-analysis [1] showed that treatment with renin-angiotensin-system inhibitors
reduces the incidence of diabetic nephropathy (primary prevention).
Despite this knowledge, the degree of glycaemic control and blood pressure
regulation does not fully explain the risk of development of diabetic nephropathy:
many people develop diabetic nephropathy despite tight glycaemic control, while
others have poor control without any evidence of diabetic nephropathy. As such,
other factors must be involved in the development of diabetic nephropathy as
well. Currently, in type 1 diabetes mellitus, the presence of microalbuminuria is
the strongest predictor for the development of diabetic nephropathy. However,
the presence of microalbuminuria could be regarded as the first presentation of
diabetic nephropathy instead of being a predictor.
In 1994 we started a prospective study in one hundred and forty-eight type 1
diabetes patients, without microalbuminuria. In this study we tried to identify
other risk factors besides poor glycaemic control and hypertension, responsible
for the development of microalbuminuria. Fifty control subjects, without diabe-
tes mellitus, were also studied for reference.
This study was designed to test four main hypotheses:
Inherited hypertension A family history of hypertension predisposes to the devel-
opment of diabetic nephropathy. Besides, an increased Na-Li countertransport
(NaLiCT) is considered a genetic marker for essential hypertension. NaLiCT
activity reflects the activity of the Na+-H+-transporter, which is involved in reg-
ulation of cell volume, cell-pH and cell proliferation. Also, increased NaLiCT
activity is associated with insulin resistance. The percentage of patients with
type 1 diabetes mellitus with an increased NaLiCT corresponds with the per-
centage of patients who finally develop diabetic nephropathy. Increased NaLiCT
activity may be a prognostic marker for the development of diabetic nephropa-
thy. Prospective data, however, are lacking. Therefore we hypothesised that an
increased NaLiCT could be a prognostic marker for the development of diabetic
nephropathy.
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Introduction and outline 3
Atrial natriuretic peptide Atrial natriuretic peptide (ANP) is an endogenous pro-
tein with natriuretic and vasodilating properties. In hypervolumic states like
sodium overload, heart failure and increased fluid intake, ANP-concentrations
are increased. In type 1 diabetes, the observed increased ANP-levels could be
the consequence of increased plasma volume as insulin induces sodium-retention.
Also the extracellular volume might increase due to renal cotransport of sodium
during tubular glucose reabsorption. Besides systemic vasodilation, ANP also
induces glomerular afferent vasodilation. This leads to increased glomerular cap-
illary pressure and increased glomerular filtration. We hypothesised that altered
baseline ANP-levels and altered physiological response to exogenous ANP could
be a prognostic marker for the development of diabetic nephropathy.
Endothelial dysfunction The endothelium plays a principal role in the regulation
of vascular tone and therefore blood pressure regulation and tissue perfusion. It
has been suggested that the presence of microalbuminuria reflects vascular dis-
function. Animal studies have shown that in hypertension, diabetes mellitus and
hypercholesterolaemia, endothelial dependent vasodilation is diminished. Inte-
restingly, early in the course of type 1 diabetes mellitus, basal flow seems to be
increased. This could be caused by increased basal nitric oxide production. We
hypothesised that altered endothelial function could be an early prognostic factor
in the development of diabetic nephropathy.
Heparan-sulphate-proteoglycan The glomerular basement membrane (GBM) is a
negatively charged size and charge selective barrier. The heparan-sulphate side
chains of heparan-sulphate-proteoglycans determine this negative charge and are
therefore responsible for the charge selective permeability of the GBM. Decreased
presence of heparan-sulphate (HS) leads to increased permeability of the GBM
to negatively charged molecules like albumin. Structural changes in the heparan-
sulphate-proteoglycan-complex (HSPG) may lead to increased permeability of
albumin and therefore (micro-)albuminuria. Interestingly, in diabetes increased
capillary permeability seems not to be confined to the glomerulus. Therefore, it
has been postulated that the presence of microalbuminuria reflects widespread
vascular damage (Steno-hypothesis). We hypothesised that alterations in the
heparan-sulphate-proteoglycan-complex is an early marker for the development
of diabetic nephropathy.
The pathophysiology of diabetic nephropathy consists of more than the four above
mentioned hypothesis. We decided to confine our research project to these hy-
potheses.
Our study specifically addresses the following hypotheses:
 The development of diabetic nephropathy in type 1 diabetes mellitus can
be predicted by the kinetic parameters of the NaLi-countertransport.
i
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4 CHAPTER 1
 The development of diabetic nephropathy is preceded by increased glomeru-
lar permeability response to atrial natriuretic peptide.
 The development of diabetic nephropathy is preceded by increased basal
production of endothelial derived relaxation factor (nitric oxide).
 The development of diabetic nephropathy is preceded by changes in the
heparan-sulphate-proteoglycan-complex, as reflected in serum and/or urine
concentrations of HS/HSPG.
We performed an extensive series of measurements and investigations in all
patients and control subjects to collect the baseline characteristics necessary to
test the above mentioned hypotheses. Renal function tests, before and during the
infusion of ANP were performed. Endothelial function was assessed by means of
forearm venous occlusion plethysmography. For this purpose NG-monomethyl-L-
arginine (L-NMMA), norepinephrine and acetylcholine were infused intraarterially
during these tests. Blood was taken to determine the kinetic parameters of the
NaLi-countertransport. Besides many other parameters were assessed. Blood was
also taken for DNA-analysis. Urine was collected for determination of HS/HSPG-
concentrations. The type 1 diabetes patients were regularly screened for the
development of microalbuminuria.
Outline of the thesis
In 1994 we started this prospective study in one hundred and forty-eight type 1
diabetes patients, without diabetic nephropathy. For reference, 50 control sub-
jects without diabetes mellitus, also underwent the investigations at baseline.
These subjects were not followed.
After baseline investigations, patients were followed for up to 13 years for the
development of microalbuminuria. At the end of the study patients who developed
microalbuminuria would be compared with those who did not develop microalbu-
minuria.
Chapter 2 reviews the current concepts of the pathophysiology of diabetic renal
microvascular complications.
During follow up, several cross-sectional studies were performed. Results of
those studies are described in chapters 3 to 8.
Renal physiology Early in the course of diabetes, the kidneys hypertrophy, and
glomerular filtration is increased. This increased glomerular filtration is (partly)
held responsible for the development of diabetic nephropathy, as it can lead to
increased glomerular pressure. These haemodynamic changes may cause injury
to the capillary wall, resulting in increased permeability, mesangial sclerosis and
glomerular basement membrane thickening. An increase in glomerular filtration
i
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Introduction and outline 5
rate could result from primary actions at the glomerular/vascular level (affer-
ent vasodilation) or could be the consequence of a primary increase in proximal
tubular sodium reabsorption resulting in systemic volume expansion. Recently it
was hypothesised that an increase in sodium reabsorption may lead to glomeru-
lar hyperfiltration through the tubulo-glomerular feedback mechanism (tubular-
hypothesis) without volume expansion. Chapter 3 describes the results of our
study in which we investigated this hypothesis.
Homocysteine has long been regarded as a (causal) factor for atherosclerosis
and as an independent risk factor for cardio-vascular disease. Despite the fact
that type 1 diabetes mellitus is often complicated by vascular disease, plasma ho-
mocysteine levels are reduced in type 1 diabetes mellitus. Plasma homocysteine
levels appear to be determined by glomerular filtration. As (early) type 1 dia-
betes mellitus is characterized by increased glomerular filtration, we investigated
whether the increased glomerular filtration could contribute to reduced plasma
homocysteine levels. Chapter 4 describes the results of an analysis in our cohort
with regard to the influence of renal function on plasma homocysteine levels.
Urinary albumin excretion is not only determined by glomerular permeability,
but also by tubular reabsorption. An increase of albuminuria could be the result
of a diminished tubular protein reabosroption. In an earlier study [2] we investi-
gated the effects of atrial natriuretic peptide on tubular protein handling. In this
study we found that atrial natriuretic peptide markedly attenuated the proximal
tubular resorption of low-molecular-weight proteins. Therefore it seemed likely
that increased albuminuria after infusion of atrial natriuretic peptide results from
blockade of tubular albumin reabsorption.
In chapter 5 and chapter 6, however, we describe the role of the polygeline
Haemaccel® (the solvent of ANP) on tubular protein reabsorption.
Endothelial function Endothelial dysfunction is thought to play an important role
in the developent of hypertension and atherosclerosis. Nitric oxide (NO), formerly
known as endothelial derived relaxation factor, plays an important role in arte-
riolar vasodilation. Alterations in NO-synthase activity could lead to decreased
vasodilation and hypertension. Chapter 7 describes the role of the Glu298Asp-
polymorphism of the NO-synthase gene on basal NO production.
In the past decades, the endothelial release of nitric oxide (NO) has been
shown to be one of the key regulators of baseline vascular tone. The optimal
method to assess the contribution of NO to baseline vascular tone is to quantify
the vasoconstrictor response to specific blockade of endothelial NO-synthase. In
humans, this is almost exclusively performed by the infusion of the NO-synthase
blocker NG-monomethyl-L-arginine (L-NMMA) into the brachial artery using the
perfused forearm technique. However up to now, dosages did not exceed 0.4
mg·min−1 per dL of forearm tissue (or 4 mg·min−1 in total, equivalent to ±16
µmol·min−1), and at this dose a maximal vasoconstrictor response to L-NMMA
is not achieved. As such, an accurate assessment of the contribution of NO to
i
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6 CHAPTER 1
baseline vascular tone is missing in the current literature. In chapter 8 we describe
the results of a pharmacodynamics study of L-NMMA using the perfused forarm
technique.
Population study In 1994, at the start of the study, it was estimated that 25-40% of
type 1 diabetes patients would develop microalbuminuria. However, after thirteen
years of follow up, only 6 patients (4%) had developed microalbuminuria. Why
did so few people develop diabetic nephropathy? Did we only include the patients
with good metabolic control? What went wrong with the inclusion? Chapter 9
compares the cumulative incidence of patients with type 1 diabetes mellitus who
participated in the study, with the eligible, but non-participating type 1 diabetes
patients.
To investigate changes in the cumulative incidence of diabetic nephropathy
over time, and to investigate which factors might be responsible for the presumed
decline in incidence, a retrospective population study was carried out. The results
of this study are described in chapter 10.
The results are summarised and discussed in chapter 11.
Een nederlandstalige samenvatting staat in hoofdstuk 12.
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Pathogenesis of renal
microvascular complications in
diabetes mellitus
Neth J Med. 2002;60:390-396
B.A.J. Veldman
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8 CHAPTER 2
Introduction
Microvascular disease is the main determinant in the development of late compli-
cations in diabetes mellitus. This is obvious for diabetic nephropathy [3; 4] and
retinopathy [5; 6], but changes in the microcirculation may also play an important
role in the pathogenesis of diabetic neuropathy [7; 8]. Although the pathogen-
esis of diabetic microangiopathy is incompletely understood, it is likely that it
involves an interaction between metabolic and functional/haemodynamic factors.
Together with genetic and environmental factors this results in the development
of microvascular complications.
Epidemiology
Diabetic nephropathy is a major cause of morbidity and mortality in patients with
type 1 as well as type 2 diabetes. Diabetic nephropathy is characterised by spe-
cific morphological changes including glomerular basement membrane thickening,
mesangial expansion and glomerular and tubulo-interstitial sclerosis. The clinical
syndrome of diabetic nephropathy exists of proteinuria, hypertension and pro-
gressive decrease of glomerular filtration rate. Various studies reveal cumulative
incidence rates for diabetic nephropathy of 20-40% [9–11], but it is suggested that
the incidence is declining [12]. Although the incidence of diabetic nephropathy
among diabetic patients is decreasing, the prevalence of nephropathy among the
population as a whole is dramatically increasing, predominantly due to improved
treatment of hypertension and coronary heart disease, and due to an increase in
prevalence of type 2 diabetes mellitus. The risk of diabetic nephropathy among
type 2 diabetic patients with progression to end-stage renal disease is compara-
ble to that in type 1 diabetes mellitus [13; 14]. The peak incidence of diabetic
nephropathy is between 10-17 years after the onset of diabetes [10; 15]. There-
after, the incidence of diabetic nephropathy declines rapidly. The first clinical
manifestation of diabetic nephropathy is microalbuminuria, defined as a urinary
albumin-excretion rate of 20-200 µg ·min−1. Microalbuminuria is associated with
other microvascular complications as well as with cardiovascular disease suggest-
ing some common pathophysiological mechanisms [9; 16].
Pathophysiology
The pathophysiology of renal microvascular complications in diabetes mellitus
consists of an intensive interplay of metabolic and functional/haemodynamic fac-
tors that underlies the structural changes of the microvasculature.
Structural changes
These structural abnormalities in diabetic glomerulopathy include an increase
in basement membrane thickness, mesangial expansion with accumulation of ex-
i
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Renal microvascular complications 9
tracellular matrix components (ECM) and glomerular fibrosis. There is an in-
verse correlation between heparan sulphate proteoglycan (HSPG) expression and
mesangial expansion in diabetic glomerulopathy [17], stressing the importance of
dysregulation of ECM synthesis what seems crucial for the development of renal
microvascular complications. Furthermore, the extent of ECM accumulation cor-
relates strongly with the degree of tubulointerstitial fibrosis and of renal failure
and proteinuria [17–20]. Tubulointerstitial injury is probably a major feature of
disease progression [21]. Chronic interstitial injury usually follows the onset of
glomerular proteinuria. Both structural lesions are probably linked via the in-
crease in glomerular permeability and ultrafiltration of bioactive (growth) factors
which can be hold responsible for inducing and/or aggravating ECM production
and renal fibrosis.
Metabolic pathways
Several factors such as high glucose, intracellular polyols, non-enzymatic glyca-
tion products, hexosamines and vasoactive hormones are hold responsible for the
changes in regulation of the biosynthesis of matrix components composition and
accumulation [22]. They stimulate the synthesis and release of growth factors
and cytokines from resident renal cells, inducing cell proliferation and hypertro-
phy, as well as the production of extracellular matrix proteins [23]. Of these,
the profibrotic cytokine, transforming growth factor-β (TGF-β) has emerged as a
key factor in the development of structural abnormalities in diabetic nephropathy
[24]. In vitro experiments showed that glomerular mesangial cells, epithelial cells
and interstitial fibroblasts increased their TGF-β expression when exposed to high
glucose [25; 26]. Also, in vivo, the expression of renal TGF-β is increased in ex-
perimental as well as in human diabetes [27; 28]. In animal models, neutralizing
TGF-β antibodies prevented the increase in extracellular matrix components and
the increase in mRNA encoding for type IV collagen a1 and fibronectin. Further-
more, anti-TGF-β almost completely prevented the fall in creatinine clearance
in diabetic db/db mice [29]. Except for ECM accumulation, it is suggested that
changes in the heparan sulphate chains of HSPG in glomerular basement mem-
branes and ECM play a role in diabetic renal disease. A decrease in heparan
sulphate, the anionic side chain of HSPG, induces proteinuria, stressing the im-
portance of heparan sulphate for the permselectivity of the glomerular basement
membrane [30]. It has been suggested that proteinuria itself plays a pathogenic
role in diabetic nephropathy [31]. However, in contrast to the prevention of the
decrease in glomerular filtration rate, neutralizing TGF-β antibodies did not pre-
vent proteinuria in diabetic mice [29]. This could implicate that the detrimental
effects of proteinuria on renal function are mediated via TGB-β or that proteinuria
is just a consequence of permselectivity changes. Nevertheless, heparan sulphate
also determines the local concentration, compartmentalisation, stability and ac-
tivity of certain growth factors and proteases, thus controlling ECM expansion
[32]. Heparan sulphate is probably directly involved in the inhibition of TGF-β
i
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10 CHAPTER 2
overexpression [33] and regulates the expression of decorin, an extracellular matrix
protein that inactivates TGF-β [34].
Hyperglycaemia The link between ECM accumulation via TGF-β and other profi-
brotic cytokines and diabetes is met by metabolic changes characteristic for the
diabetes state per se. The metabolic hypothesis suggests that microvascular
complications develop as a direct consequence of hyperglycaemia. Several small,
prospective, randomised intervention studies and the DCCT [35] have definitely
proven that improved metabolic control achieving near-normoglycaemia can re-
duce the incidence of diabetic nephropathy. These studies have revealed duration
and severity of hyperglycaemia as major risk factors for the development of dia-
betic microvascular complications. Complete normalisation of blood glucose after
pancreas transplantation even shows a regression of structural renal changes [36].
The mechanisms by which hyperglycaemia give rise to microvascular complica-
tions has slowly been unravelled in the last years, supported by a large amount
of experimental as well as clinical data.
Advanced glycation end-products Advanced glycation end-products (AGEs), which
are formed by non-enzymatic glycation of proteins, accumulate in renal glomeruli
[37]. Recent research has shown that AGE precursors (dicarbonyls like methyl-
glyoxal) are formed intracellularly from intracellular hyperglycaemia. These pre-
cursors can react with amino groups of intra- and extracellular proteins to form
AGEs. AGEs are capable of inducing increased vascular permeability, enhancing
protein and lipoprotein deposition, inactivating nitric oxide and promoting matrix
protein synthesis and glomerular sclerosis [38]. This latter mechanism is probably
mediated by TGF-β [39; 40]. The clinical importance of AGEs in diabetic ne-
phropathy is stressed by the role of AGE formation inhibitors like aminoguanidine
and ALT-946 and the so called AGE crosslink “breakers” (phenacylthiazolium
bromide; ALT-711) for treatment or prevention of diabetic (renal) complications
[41; 42].
Protein Kinase C (PKC) An increase in intracellular glucose induces de novo syn-
thesis of diacyl glycerol (DAG) [43] that activates protein kinase C (PKC). PKC is
capable of phosphorylating a number of cellular proteins. Increased PKC activity
modulates gene expression in mesangial cells, inducing extracellular matrix pro-
tein synthesis, especially of type IV collagen and fibronectin, which is mediated
by TGF-β [24; 44]. Furthermore, PKC activation is linked to mitogen-activated
protein kinase (MAPK) which is important in the intracellular signal transduc-
tion processes leading to cell proliferation and hypertrophy [45; 46]. Activation
of PKC increases production of vasodilatory prostanoids leading to hyperfiltra-
tion [47]. Animal studies showed that blockade of PKC by means of LY333531
reversed renal hyperfiltration and reduced glomerular albumin permeability [48].
Treatment with a PKC-inhibitor showed a reduction of urinary albumin excre-
i
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tion rates and prevented mesangial expansion observed in diabetic db/db mice,
possibly through attenuation of glomerular expression of TGF-β [49].
Polyol pathway Hyperglycaemia induces an increased flux through the polyol path-
way. Originally it was thought that intracellular formation and accumulation of
sorbitol, mediated by aldose-reductase, leads to increased intracellular osmolality
and swelling of cells. However, just recently it has been shown that decreased
levels of reduced glutathione (GSH), as a consequence of the reduction from glu-
cose to sorbitol [50], are responsible for the deleterious consequences by increasing
intracellular oxidative stress (see below). Clinical trials suggested the potential
usefulness of aldose reductase inhibitors in preventing the progression of incipient
diabetic nephropathy in patients with type 2 diabetes mellitus [51].
Hexosamine pathway In diabetes an increased flux of intracellular glucose through
the hexosamine pathway results in increased N-acetylglucosamine (GlcNAc), by
conversion from fructose-6-phosphate by the enzyme GFAT. Most probably, mod-
ification of transcription factors like Sp1 by GlcNAc will lead to transcription of
the gene for TGF-β [51]. Furthermore, many other intracellular proteins are mod-
ified by GlcNAc like eNOS activity [51] that may contribute to the pathogenesis
of renal diabetic complications.
Reactive Oxygen species as a common pathway Recently, Nishikawa et al. [52], and
Du et al. [53] have shown that the formation of AGEs, activation of PKC, and
activation of the polyol pathway as well as the hexosamine pathway, are mediated
by the production of reactive oxygen species (ROS). They showed that elevated
(intracellular) glucose levels increase the production of ROS in mitochondria. This
overproduction of ROS was prevented by manganese superoxide dismutase or by
an uncoupler of oxidative phosphorylation, by uncoupling protein-1, and com-
pletely prevented intracellular formation of AGEs, activation of protein kinase C,
increase in polyol pathway flux and hexosamine pathway activation. They con-
cluded that ROS-production is a common-pathway in the initiation of high-glucose
mediated stimulation of the aforementioned pathways. It is hypothesised that an
excess of ROS inhibits GADPH (glyceraldehyde-3-phosphate dehydrogenase), a
glycolytic key-enzyme, promoting shunting of upstream glucose-metabolites into
the aforementioned pathways.
Functional/haemodynamic pathway
Long-lasting poor metabolic control does not necessarily lead to diabetic microvas-
cular disease. This means that the apparent protection of diabetic patients for
nephropathy cannot solely be explained on the basis of better metabolic control.
The haemodynamic hypothesis implies that due to haemodynamic alterations in
i
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12 CHAPTER 2
blood flow and pressure, structural changes are provoked, which will result in the
development of microvascular complications.
Flow/pressure (haemodynamic hypothesis) Capillary hyperperfusion precedes the
onset of diabetic renal microangiopathy [4]. This observation has led to the hy-
pothesis that changes in systemic or local haemodynamics contribute to the de-
velopment of diabetic nephropathy [54]. Micropuncture studies revealed a range
of haemodynamic alterations in diabetes: increased intraglomerular pressure, in-
creased singel nephron GFR and preferential afferent compared with efferent ar-
teriolar vasodilation. These renal haemodynamic changes may be related to va-
soactive hormones such as angiotensin II, endothelin, nitric oxide, locally active
prostaglandins and kinins, and atrial natriuretic peptide. Furthermore, hyper-
glycaemia, glucagon, insulin, insulin-like growth factor and reduced sympathetic
nerve activity may be involved in diabetic microvascular haemodynamic changes.
These haemodynamic changes cause injury of the vascular wall, resulting in in-
creased permeability, intima fibrosis, and vascular smooth muscle cell proliferation
[55]. Therapy aimed at reversing glomerular hyperfiltration, by controlling glucose
concentration early in the course of the disease, dietary protein restriction, and
antihypertensive therapy, may slow the rate of progression of the renal disease.
Currently many pharmacological substances are being developed which block the
effect of vasoconstrictory hormones, or reduce the degradation of vasodilating
hormones. Because most of the enzymes involved in production and degradation
of these vasoactive hormones have considerable homology, substances are being
developed which interact with more than one of these systems.
Renin-Angiotensin System (RAS) The therapeutic effects of angiotensin converting
enzyme (ACE) inhibitors and AT1-receptor antagonists in decreasing the pro-
gression of micro- or macroalbuminuria stresses the importance of the Renin-
Angiotensin System (RAS) [56–60]. The decrease in progression of diabetic ne-
phropathy by ACE-inhibitors and AT1-receptor antagonists was originally at-
tributed to their ability to control systemic and intraglomerular hypertension.
However, despite comparable reductions in systemic blood pressure, endothelin
receptor blockade was not as renoprotective as an ACE-inhibitor at least in rats
[61]. Indeed, aforementioned studies showed that effective blockade of angiotensin
II action had favourable renoprotective effects that go beyond the blood pressure
lowering effects of these drugs. Thus, it is likely that some of these favourable
effects might be related to the non-haemodynamic effects of angiotensin II. An-
giotensin II induces smooth muscle cell growth, hypertrophy and proliferation of
glomerular cells and stimulates the synthesis of ECM components, collagen and
fibronectin. The angiotensin II induced smooth muscle cell growth and the hy-
pertrophic and fibrogenic responses are mediated by TGF-β [62]. Neutralising
anti-TGF-β antibodies are able to prevent angiotensin II stimulated production
of ECM in in vitro studies with mesangial cells [63]. Furthermore, angiotensin II
i
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Renal microvascular complications 13
activates PKC in glomerular cells through AT1 receptor stimulation.
Endothelial dysfunction The normal endothelium has important regulating pro-
perties for vascular tone and is intimately involved in the regulation of vascular
and renal permeability. It regulates the composition of ECM and the prolif-
eration of smooth muscle and mesangial cells [64]. Therefore, endothelial dys-
function has been implicated in the pathogenesis of diabetic vascular disease.
In non-complicated type 1 diabetic patients acetylcholine induced endothelial-
dependent vasodilatation is intact [65]. In contrast, diabetic microalbuminuria
reflects widespread endothelial dysfunction. An increase in von Willebrand Factor
(vWF), a component of the endothelial cell membrane and a marker of endothelial
damage, precedes the occurrence of microalbuminuria [66]. The mechanisms by
which diabetes causes impaired endothelial function are largely unknown. In view
of the haemodynamic changes in diabetes a biphasic process is proposed. As a
vasodilator, nitric oxide (NO) is a candidate for mediating the increases in blood
flow and capillary permeability that are observed in the early phase of diabetes.
Indeed, an increased basal endogenous NO production accounts for the renal hy-
perfiltration in diabetic rats, whereas in the kidney there seems to be an enhanced
nitric oxide production indicated by an increased urinary nitrate and nitrite con-
centration [67; 68]. The cause of the increased renal nitric oxide production is not
elucidated yet. There are reports of an increased expression of inducible Nitric
Oxide Synthase (iNOS) [69], but animal studies showed that l-imino-ethyl-lysine,
a specific inhibitor of iNOS, was unable to reduce the glomerular hyperfiltration
[70]. Furthermore NO was not increased in normoalbuminuric tye 1 diabetic pa-
tients using the isolated forearm technique [65]. Deficiency of nitric oxide in the
vascular tree is a duration dependent process. Therefore, late in the course of
diabetes, damaged endothelial cells may loose the ability to increase NO synthe-
sis, thus favouring a proliferative and thrombogenic milieu. It is suggested that
endothelial dysfunction could be the result of hyperglycaemia induced formation
of free radicals, which inactivate nitric oxide (NO). In vitro, the bioavailability of
NO is reduced by AGEs, which quench NO [38]. Also, hyperglycaemia interferes
with the production of cyclic guanylate monophosphate (cGMP), the second mes-
senger of NO. Hyperglycaemia is also capable of activating protein kinase C that
inhibits endothelial NO-synthase [44].
Of interest, recently it was suggested that activation of poly(ADP-ribose)
polymerase (PARP) is an important factor in the pathogenesis of endothelial
dysfunction in diabetes. Inhibition of PARP by a novel PARP inhibitor PJ34,
maintained normal vascular responsiveness, despite persisting hyperglycaemia in
diabetic mice [71].
Genetic influences
In contrast to diabetic retinopathy and neuropathy, which develop in the majority
of diabetic patients, only 20-40% of type 1 diabetic patients are at risk of develop-
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ing diabetic nephropathy. In view of the observed familial clustering of diabetic
nephropathy, a genetic predisposition to diabetic nephropathy has been assumed.
From epidemiological studies evidence appears about genetic influences on the de-
velopment of microvascular complications [72–74]. The genetic susceptibility may
also explain the marked differences in incidence of microvascular complications
between various races [75]. A genetic predisposition to and a parental history of
hypertension are supposed to be risk factors for the development of diabetic ne-
phropathy [76]. The likelihood of developing diabetic nephropathy was increased
in patients with an elevated sodium-lithium countertransport activity, a marker
of the genetic predisposition to essential hypertension [77]. As both hypertension
and the development of diabetic nephropathy seem to be genetically determined,
it is tempting to search for combined genetic markers. Genes involved in the RAS
are promising candidates as the RAS plays a central role in both blood pressure
regulation and renal function. Association studies linking these polymorphisms
with the development of diabetic nephropathy reveal conflicting results. Many re-
ports on ACE-polymorphisms suggest a contribution of the DD polymorphism in
the development of diabetic nephropathy [78], although a recent thorough review
by Kunz et al. [79] failed to confirm the suggested association due to method-
ological limitations in the original studies.
Conclusions
The pathophysiology of renal diabetic microvascular complications is slowly being
unravelled now. Metabolic and haemodynamic changes interfere in which TGF-β
seems to play a central role. There is also strong evidence that hereditary factors
are essential in the development of microvascular complications. This suggests
that the development of diabetic microvascular complications is a multifacto-
rial process in which different mechanisms are likely to operate. Elucidating the
pathophysiology of microvascular complications is important for the development
of appropriate prevention and treatment of these complications.
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Glomerular hyperfiltration in type 1
diabetes mellitus results from
primary changes in proximal tubular
sodium handling without changes in
volume expansion
Eur J Clin Invest. 2005;35:330-336
G. Vervoort
B.A.J. Veldman
J.H.M. Berden
P. Smits
J.F.M. Wetzels
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Abstract
Background Glomerular hyperfiltration plays a role in the pathophysiology of di-
abetic nephropathy. An increase in glomerular filtration rate (GFR) could result
from primary actions at the glomerular/vascular level or could be the conse-
quence of a primary increase in proximal tubular sodium reabsorption resulting
in systemic volume expansion. Recently it was hypothesized that an increase in
sodium reabsorption may lead to glomerular hyperfiltration through the tubulo-
glomerular feedback mechanism (tubular-hypothesis) without volume expansion.
Methods We have studied 54 normoalbuminuric patients with type 1 diabetes.
GFR was measured by inulin clearance. Proximal and distal sodium reabsorp-
tion were calculated according to standard formulas using free water clearance
technique. Plasma volume, measured by 125I-albumin method, atrial natriuretic
peptide (ANP) and the second messenger cyclic guanosine-3,5-monophosphate
(c-GMP) were used as markers of extracellular volume expansion.
Results Glomerular hyperfiltration (GFR≥ 130mL·min−1·1.73m−2) was present
in 14 out of 55 diabetes patients (25%). There were no differences in plasma vol-
ume between normo- (NF) and hyper-filtrating (HF) patients (2933±423 in NF
vs 3026±562 mL in HF, NS). Also plasma ANP and c-GMP levels were not
significantly different between the groups. The fractional proximal reabsorption
of sodium was significantly increased in HF (fPRNa+(%) 90.1±2.0 vs 91.5±1.6,
p=0.02). There were no differences in distal sodium reabsorption or distal sodium
load (≈ macula densa concentration of NaCl) in both groups.
Conclusions Our data suggest that the primary event in diabetic glomerular hy-
perfiltration is an increase in proximal tubular sodium reabsorption. They do not
give support to the hypothesis that systemic volume expansion or ANP mediate
glomerular hyperfiltration in normoalbuminuric type 1 diabetes patients. As such,
changes in tubular sodium handling most probably influence tubulo-glomerular
feedback.
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Introduction
Diabetic nephropathy develops in about 10-30% of patients with type 1 diabetes
and accounts for the increased morbidity and mortality [10; 12]. Renal haemo-
dynamic changes characterized by glomerular hyperfiltration occur early after
onset of diabetes even before glomerular morphological changes can be found,
and are likely to play a role in the pathophysiology of progressive renal disease
[3; 4; 80; 81]. Glomerular hyperfiltration is attributed to vasodilatation pre-
dominantly of the afferent arteriole. Many humoral and vascular mediators have
been implicated in hyperfiltration due to their primary actions at the glomeru-
lar level. Apart from glucagon [82], insulin-like growth factor [83], locally active
prostaglandins [84] and kinins [85], nitric oxide [86; 87], hyperglycemia [88] and
angiotensin II [87] may be involved in diabetic glomerular hyperfiltration. It has
been proposed that consequences of diabetes on glomerular filtration find their
origin not primarily in the glomerulus but in a primary increase in proximal tubu-
lar sodium reabsorption. In diabetes, an increase in tubular sodium reabsorption
can be attributed to hyperglycemia or hyperinsulinemia [89–91]. Several stud-
ies have suggested that an increase in atrial natriuretic peptide (ANP) levels,
due to increased extracellular volume may be involved in diabetic glomerular hy-
perfiltration [92]. In recent years it was suggested that a primary increase in
proximal tubular reabsorption of sodium influences glomerular filtration not via
extracellular volume expansion but through the macula densa (tubulo-glomerular
feedback) [93; 94]. This is referred to as the “tubular hypothesis” of glomerular
hyperfiltration (figure 3.1). In order to find out whether a primary “glomerular“
or “tubular” event precedes glomerular hyperfiltration and to elucidate the role
of volume expansion/ANP and tubulo-glomerular feedback in the pathogenesis of
diabetic hyperfiltration, we studied baseline levels of ANP and its second mes-
senger cyclic guanosine-3,5-monophosphate (c-GMP) in relation to extracellular
volume status, tubular sodium handling and renal haemodynamics in patients
with normoalbuminuric type 1 diabetes mellitus.
Methods
Study population In 1994 we initiated a large prospective study in type 1 diabetes
patients, aiming at identifying factors involved in the development of microal-
buminuria. For this purpose we measured renal and systemic haemodynamics
including endothelial function and transcapillary escape rate of albumin in pa-
tients and matched controls. The cross-sectional results were published elsewhere
[65; 95; 96]. In a large subgroup of patients we also measured plasma-volume,
ANP and c-GMP levels as well as (fractional) sodium clearance. The analysis of
the results of these measurements is the subject of the present study.
After approval of the study protocol by the local ethics committee, 54 patients
with type 1 diabetes mellitus gave their written informed consent for participation
in the study. The diabetes patients fulfilled the following inclusion criteria: dia-
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Figure 3.1: Schematic view of possible tubular events involved in the pathogenesis of
diabetic glomerular hyperfiltration. ANP, atrial natriuretic peptide; GFR, glomerular
filtration rate; ECV, extracellular volume; MD, macula densa; TGF, tubulo-glomerular
feedback.
betes onset before the age of 40, insulin treatment within 1 year after diagnosis,
duration of diabetes of 5-12 years, age 18-40 years, blood pressure <140/90 mmHg
(mercury sphygmomanometer), no anti-hypertensive medication, no clinical evi-
dence of macrovascular disease and no evidence of nephropathy (microalbumin-
uria) or retinopathy (except for simple background retinopathy). Albuminuria
was assessed in two timed overnight urine samples. Microalbuminuria was de-
fined as a urinary albumin excretion >20 µg·min−1. The diabetes patients were
recruited from the outpatient diabetes clinic of the Radboud University Nijmegen
Medical Centre.
Study protocols All subjects were on an “ad libitum” diet the week before the
start of the study and were instructed to abstain from alcohol and caffeine con-
sumption for at least 24 h and to refrain from smoking 12 h before the experi-
ments. All participants were studied in the morning after a light breakfast. At
08.00 a.m. all subjects consumed a water load of 20mL·kg−1 and two intravenous
lines were inserted for constant infusion of 250 mL·h−1 glucose 2.5%/NaCl 0.45%
and inulin as well as for blood sampling. Inulin (Inutestr) was purchased from
Laevosan-Gesellschaft m.b.H., Linz, Austria. Plasma glucose was measured us-
ing a standard glucose oxidation method. During the study blood glucose was
measured every 20 min using a glucocard (Menarini Diagnostics, Utrecht, the
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Netherlands). Glucose levels were kept constant between 5 and 8 mmol·L−1 dur-
ing the whole study period. Additional glucose or insulin was given to maintain
target glucose levels if necessary. Extra tap water matching urine output was
supplied for the remainder of the clearance study. The subjects were supine dur-
ing the clearance study, but were allowed to stand to urinate. After 30 min a
constant infusion of inulin was started, preceded by a priming dose. After an
equilibration period of at least 70 min in which urine output was at least 10
mL·min−1, three urine samples were collected at 20 min intervals. Blood sam-
ples were taken via the intravenous cannula before and after each urine collection.
Before the start of the clearance study blood pressure was recorded in supine
position with a sphygmomanometer. During the clearance study blood pressure
was recorded twice during each urine collection with an automatic oscillometric
device (Dinamap, 1846 SX, Critikon, Tampa, Florida, USA). On a separate occa-
sion (due to practical reasons) within 2 days of the first study, in a fasting state,
plasma volume was measured using 2-4 µCi 125I-albumin (Iodinated [125I] Human
Serum Albumin, code IM 17 P, Amersham Int., Amersham, England) given as
an iv bolus injection in one arm. During the first 60 min after injection, seven
arterial blood samples were collected at regular intervals from the other arm.
Plasma radioactivity was measured in each sample using a scintillation detector
(automatic g-counter, 1480 Wizard 3”, Wallac, Turku, Finland). Plasma volume
was determined from retropolation of the disappearance curve to time zero and
from the injected volume of the tracer. Calculations were only done when the cor-
relation coefficient between time points for blood sampling and the corresponding
values of ln (plasma radioactivity) exceeded 0.85 [95; 97]. Urine and blood sam-
ples were analysed for creatinine, sodium, potassium, osmolality, and inulin using
standard laboratory procedures. Plasma concentrations of ANP and of its sec-
ond messenger c-GMP were measured in blood samples just before the start of
inulin infusion and volume loading. Plasma c-GMP was assumed to be a reflec-
tion of systemic ANP activity [98] whereas urinary c-GMP was supposed to be a
marker of the renal action of ANP [99]. ANP was measured by a radioimmunoas-
say as described previously [100]. Urinary c-GMP was measured by an enzyme
immunoassay (Biotrak c-GMP EIA, RPN 226, Amersham Life Science, Bucking-
hamshire, England). Plasma c-GMP concentration was measured with the same
immunoassay after an additional ethanol extraction. HbA1c was measured using
a HPLC technique (Bio-Rad Diamat, Veenendaal, The Netherlands) with ref-
erence values of 4.8-6.2%. The renal clearance of inulin is regarded as a marker
for glomerular filtration rate (GFR). The fractional excretion of sodium (FNa)
is calculated as quotient of clearance of sodium and GFR. Free water clearance
(CH2O) is calculated as urine volume minus osmolar clearance. Fractional and dis-
tal sodium reabsorption were calculated with the free water clearance technique
according to the following formula [101; 102]:
i
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Figure 3.2: Correlation of proximal tubular sodium reabsorption calculated with either
the free water clearance technique (fPRNa+) or lithium clearance (1-fELi+) in healthy
volunteers after administration of triamterene (), acetazolamide (), hydrochloroth-
iazide (N), ethacrynic acid (©), furosemide (×) and amiloride (•) .
Fractional proximal sodium reabsorption was calculated by:
100−
(
U(Na+K)·V
GFR·PNa ·100%
)
−
(
CH2O
GFR ·100%
)
Fractional distal sodium reabsorption (corrected for total tubular load [GFR
x PNa]) was calculated by:(
(CH2O·PNa)+(V ·UK)
GFR·PNa
)
· 100%
Fractional distal sodium reabsorption (corrected for distal load [V x PNa]) was
calculated by: (
(CH2O·PNa)+(V ·UK)
V ·PNa
)
· 100%
These formulas were validated in a pilot experiment in which we studied the
natriuretic effects of differently acting diuretics in healthy volunteers. We found a
high correlation (r2=0.76) between proximal tubular reabsorption calculated with
either free water clearance technique or lithium clearance technique as described
before [103], although the free water clearance technique evidently provided a
higher estimate of proximal tubular sodium and water reabsorption (figure 3.2).
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NF HF
(n=41) (n=13)
Females / Males 19/22 8/5
Age (years) 28±7 28±7
Weight (kg) 72±10 71±8
Body mass index (kg·m−2) 23.0±3.1 23.6±3.0
Blood pressure (mmHg) 116±9 / 62±6 117±8 / 63±6
Duration of diabetes (years) 8.5±3.1 8.3±3.0
HbA1c (%) 8.3±1.4 8.4±1.3
Albumin excretion rate (µg·min−1) 7.0±4.2 9.1±4.8
Urinary sodium excretion (mmol·24h−1) 141±47 150±61
Urinary potassium excretion (mmol·24h−1) 69±26 83±39
Values are expressed as means±SD.
Table 3.1: Baseline characteristics of the patients with diabetes. NF, patients with
diabetes with normal glomerular filtration; HF, patients with diabetes with glomerular
hyperfiltration (GFR≥130 mL·min−1·1.73m−2; BMI, body mass index; HbA1c, glycosi-
lated haemoglobin.
Statistical analysis Statistical analysis was performed using the SPSS 11.0.1 per-
sonal computer software package (SPSS Inc, Chicago, Il, USA). Differences in
baseline levels between the two groups were analysed by unpaired Student’s t-test
for normally distributed data and Mann-Whitney U test for non-parametric data.
Correlation coefficient was calculated by linear regression analysis. A p-value less
than 0.05 was considered to be statistically significant. Values are expressed as
means±SD unless otherwise indicated.
Results
Subjects characteristics Mean GFR was 121±11 mL·min−1·1.73m−2 in the dia-
betes patients. Based on studies in healthy subjects, renal hyperfiltration was
defined as a GFR ≥ 130 mL·min−1·1.73m−2 [95; 96]. Patients were divided into
those with a normal GFR (NF) and those with glomerular hyperfiltration (HF).
The characteristics of the two groups are summarised in table 3.1. There were
no demographic or anthropomorphic differences between the groups. On arrival
at the hospital, mean plasma glucose level in NF diabetes patients was 13.0±4.3
mmol·L−1 and in HF diabetes patients 12.9±4.4mmol·L−1 (NS). Throughout the
clearance study plasma glucose was 7.2±1.9 and 7.5±2.0 mmol·L−1 in NF and
HF diabetes patients respectively (NS). Insulin levels at the start of the study
were similar (116±71 pmol·L−1 in NF vs 140±118 in HF, NS). Also, there were
no differences in mean arterial blood pressure (90±7 mmHg in NF vs 88±6 in
HF, NS) or in heart rate (66±8 bpm in NF vs 70±11 in HF, NS). The urinary
flow, urinary osmolality, free water clearance, urinary sodium and potassium and
i
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NF HF p-value
(n=41) (n=13) between groups
GFR (mL·min−1·1.73m−2) 114±11 143±12 <0.0001
Urinary flow (mL·min−1) 13.8±2.3 14.7±2.4 NS
CH2O (mL·min−1) 10.5±2.0 10.8±2.4 NS
Uosm (mosmol·kg−1) 68±13 78±36 NS
Cosmol (mL·min−1) 3.3±0.7 3.8±0.8 NS
UNa+ (mmol·L−1) 11.0±4.3 11.4±6.5 NS
UK+ (mmol·L−l) 5.0±2.0 6.4±2.7 NS
PNa+ (mmol·L−1) 138±2 137±2 NS
Plasma ANP (nmol·L−1) 7.6±2.8 7.7±1.7 NS
Plasma c-GMP (nmol·L−1) 3.1±2.4 2.7±1.0 NS
Urinary c-GMP (nmol·L−1) 28.6±8.8 31.0±8.8 NS
Fractional c-GMP excretion (%) 122±47 125±40 NS
FENa+ (%) 0.87±0.37 0.71±0.32 NS
Proximal FRNa+ (%) 90.1±2.0 91.5±1.6 0.02
Distal FRNa+ (%†) 9.0±1.8 8.1±1.3 0.07
Distal FRNa+ (%§) 80.0±3.2 79.5±4.0 NS
MD[NaCl] (µmol·min−1) 1.9±0.3 2.0±0.3 NS
Values are expressed as means±SD.
Table 3.2: Results of renal clearance study and calculations of tubular sodium han-
dling. NF, diabetes patients with normal glomerular filtration; HF, diabetes patients
with glomerular hyperfiltration (GFR ≥ 130 mL·min−1·1.73m−2). GFR, glomerular
filtration rate; CH2O Free water clearance; Uosm, urinary osmolality; Cosmol, osmolar
clearance; UNa+ , urinary sodium concentration; UK+ , urinary potassium concentration;
PNa+ , plasma sodium concentration; ANP, atrial natriuretic peptide; c-GMP, cyclic
GMP; MD[NaCl], reflection of sodium chloride concentration in macula densa ∼ distal
load; FENa+ , fractional excretion of sodium; FRNa+ , fractional reabsorption of sodium.
† corrected for tubular load; §corrected for distal load. NS, not significant.
plasma sodium were similar in both groups (table 3.2).
Tubular sodium handling The mean urinary sodium excretion was not different be-
tween the groups reflecting an average dietary salt intake of 9 grams per day (table
3.2). The fractional proximal sodium reabsorption was significantly higher in the
HF group. To appreciate this difference we calculated the effect of an increase
in fractional sodium reabsorption in relation to GFR. In patients with normal
GFR, an average fractional proximal sodium reabsorption of 90.1% and a GFR
of 114 mL·min−1 mean an average proximal sodium reabsorption of 114 × 1.44
× 140 × 0.901 = 20707 mmol·day−1; in HF patients this is 143 × 1.44 × 140 ×
0.915 = 26378 mmol·day−1. This reflects an increase of 27% in proximal sodium
handling. Fractional distal sodium reabsorption (corrected for total tubular load
i
i
“thesis” — 2009/9/17 — 20:34 — page 23 — #29 i
i
i
i
i
i
Hyperfiltration due to changed proximal sodium resorption 23
Figure 3.3: Correlation between fractional proximal sodium reabsorption and glomeru-
lar filtration rate
and for distal load) was not different. There were no significant differences in
distal tubular load of sodium (V× PNa+) in both groups, reflecting macula densa
sodium exposure (MD[NaCl]). There was a significant and fairly high correla-
tion between fractional proximal sodium reabsorption and GFR in the diabetes
patients (r2=0.29, p<0.01) (figure 3.3).
Plasma volume, plasma ANP and c-GMP levels and urinary c-GMP excretion Mean plas-
ma volume was not significantly different between both groups. Plasma volume
was 2933±623 mL (2755±430 mL·1.73m−2) in NF and 3026±562 mL (2923±360
mL·1.73m−2) in HF. Plasma ANP levels were similar in both groups (table 3.2).
We found no significant correlation between plasma ANP levels and GFR or
plasma volume in our study group (data not shown). Plasma c-GMP was not
significantly different between groups. Also, urinary concentration of c-GMP as
well as fractional excretion of c-GMP did not differ significantly. There were no
significant correlations between plasma c-GMP and plasma volume or urinary
c-GMP and GFR (data not shown).
Discussion
Our study indicates that glomerular hyperfiltration in normoalbuminuric type 1
diabetes mellitus is related to an increase in fractional proximal sodium reab-
sorption. A primary “glomerular” event resulting in an increase in GFR should
be expected to lower fractional proximal sodium reabsorption due to imperfect
glomerulotubular balance. As such an increase in fractional reabsorption cannot
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be the consequence of a primary glomerular effect leading to glomerular hyper-
filtration. Since hyperfiltration was found in the absence of extracellular vol-
ume expansion, the present findings are consistent with a primary increase in
tubular reabsorption upstream to the macula densa increasing GFR via tubulo-
glomerular feedback. Therefore, our data are in support of the so-called “tubular
hypothesis of diabetic hyperfiltration. Normally GFR is maintained by primary
glomerular/vascular events, tubulo-glomerular feedback and the glomerulotubular
balance. Primary glomerular/vascular effects on GFR cause a change in tubular
reabsorption through the physiological action of the glomerulotubular balance.
When glomerulotubular balance functions normally, fractional reabsorption de-
clines as GFR increases [93]. In other words, a primary increase in GFR should
not increase fractional tubular sodium reabsorption as shown in our study. As
such, a primary tubular event should be expected to be involved in diabetic hy-
perfiltration. Using lithium clearance techniques an increased proximal sodium
reabsorption has been noted before in type 1 diabetes patients [104–106]. Theoret-
ically, this increase in proximal sodium reabsorption could cause volume expansion
resulting in glomerular hyperfiltration. However, an increase in extracellular fluid
volume is not a uniform finding in patients with diabetes. In our study extracel-
lular volume, assessed by measurements of plasma volume and ANP levels (and
c-GMP), did not differ between NF and HF patients. Our data are in seem-
ingly contrast with studies that have reported increased levels of ANP in diabetes
patients as a reflection of increased extracellular volume [107–109]. However, in
most of these studies diabetes patients were studied either during a hyperinsuline-
mic euglycemic clamp or without metabolic control. The expanded extracellular
volume, as a result of the hyperinsulinemia or hyperglycemia could be an expla-
nation for these raised ANP levels [90; 110]. Indeed, in diabetes patients studied
under conditions similar to ours normal ANP levels were reported [111]. In recent
years, it is hypothesized that the increase in proximal tubular sodium reabsorp-
tion could be the primary event in a cascade leading to glomerular hyperfiltration
involving macula densa mechanisms (tubular hypothesis) [93; 94]. The increased
proximal sodium reabsorption will decrease salt delivery to the macula densa
(MD[NaCl]). Via tubulo-glomerular feedback this will increase GFR (hyperfiltra-
tion) thus restoring distal salt delivery. The primary increase in proximal sodium
reabsorption in diabetes has been linked to tubular hypertrophy [112] and/or
an increase in sodium-glucose cotransporters [111]. Indeed, sodium-glucose co-
transporters were up-regulated in diabetic rat renal cortex [113]. In our study
fractional proximal sodium reabsorption was increased in HF patients. Distal
sodium was not different between the groups. Our findings thus are compatible
with the abovementioned concept. We showed that in our study fractional prox-
imal sodium reabsorption was indeed well correlated with GFR, although we are
aware of the fact that it does not prove causality. The changes in proximal tubular
salt reabsorption in diabetes patients not only explain diabetic hyperfiltration but
also the so called “paradoxical effect of dietary salt intake on GFR in diabetes
[114]. Salt balance is normally maintained by changes of sodium reabsorption
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downstream of the macula densa under the control of aldosterone. In diabetes
the proximal tubule is more sensitive to changes in dietary salt. As a consequence
tubulo-glomerular feedback signal is strongly influenced by dietary salt such that
consuming more salt will lead to an augmented activation of tubulo-glomerular
feedback (and a decrease in GFR) and vice versa. Few studies indeed found such
an effect of low salt intake and a concomitant increase in GFR in human diabetes
[115; 116]. We could not confirm these data by plotting 24 h urinary sodium ex-
cretion (as a measure of dietary sodium intake) to GFR in the diabetes patients.
However we did not put the study subjects on a low and high sodium diet, which
was properly done in the aforementioned studies. Finally it can be appreciated
that inhibition of proximal sodium reabsorption by acetazolamide lowers GFR.
This effect is even more prominent in diabetes patients emphasizing the increased
proximal sodium reabsorption in these patients [117; 118].
We conclude that in normoalbuminuric type 1 diabetes glomerular hyperfil-
tration seems to be related to a primary increase in proximal tubular sodium
reabsorption. Since in our patients there was no evidence of expansion of plasma
volume and/or an increase in ANP, changes in tubular sodium handling most
probably influence tubulo-glomerular feedback.
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Reduced plasma total homocysteine
concentrations in type 1 diabetes
mellitus is determined by increased
renal clearance
Diabet Medicine 2005;22:301-305
B.A.J. Veldman
G. Vervoort
H. Blom
P. Smits
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Abstract
Introduction Elevated plasma levels of total homocysteine (tHcy) are related to
the development of vascular complications. Patients with diabetes mellitus are
particularly at risk for the development of these complications. Several factors
determine tHcy including renal function.
Aims As early type 1 diabetes is characterised by a relative glomerular hyper-
filtration, increased renal clearance could contribute to decreased levels of homo-
cysteine as observed in type 1 diabetes mellitus. Therefore we investigated the
relationship between tHcy and the glomerular filtration rate (GFR).
Methods In 92 type 1 diabetes patients and 44 control subjects we measured
GFR and effective renal plasma flow (ERPF) by means of continuous infusion of
inulin and p-aminohippurate. Fasting tHcy was measured using high performance
liquid chromatography.
Results GFR (121±21 resp. 104±14 mL·min−1; p<0.001) and ERPF (563±127
resp. 516±121 mL·min−1; p=0.05) were significantly higher in type 1 diabetes
patients as compared with control subjects. tHcy was reduced in type 1 diabetes
patients as compared with control subjects (11.0±4.5 resp. 13.4±7 µmol·L−1;
p=0.01). tHcy was strongly correlated with GFR (type 1 diabetes patients: R=
-0.43, p<0.001; control subjects: R= -0.39, p=0.01).
Conclusion GFR is a major determinant of tHcy levels in type 1 diabetes patients
as well as control subjects. The reduced tHcy levels in diabetes patients can be
explained by an increased GFR.
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Introduction
Epidemiological, experimental and clinical studies show that elevated plasma
levels of the amino acid homocysteine relate to vascular complications. Sev-
eral factors determine plasma total homocysteine (tHcy) including plasma levels
of vitamin B12, vitamin B6 and folic acid, mutations of genes involved in ho-
mocysteine metabolism (methylenetetrahydrofolate reductase, cystathionine β-
synthetase) and renal function. The importance of renal clearance of homocys-
teine is most clearly shown in patients with end-stage renal disease as virtually
all of these patients show strongly increased tHcy levels [119–121]. These pa-
tients have a high risk for macrovascular disease. Patients with diabetes mellitus
are particularly at risk for the development of macrovascular disease. However,
there are some reports of reduced tHcy in type 1 diabetes mellitus [122; 123]. As
glomerular hyperfiltration is highly prevalent in type 1 diabetes, increased renal
clearance could contribute to decreased levels of homocysteine as observed in type
1 diabetes mellitus. Wollesen et al. [122] studied the relationship between renal
clearance and tHcy in a mixed type 1 and type 2 diabetes population. They
showed a significant correlation between tHcy and the glomerular filtration rate
(GFR). In their study patients with microvascular complications were included
as shown by the presence of microalbuminuria. Besides, many patients had hy-
pertension. Therefore we studied the relationship between tHcy and GFR using
the continuous infusion of inulin and p-aminohippurate clearance method, both
gold standards to measure GFR and ERPF, in type 1 diabetes patients without
renal and macrovascular complications and control subjects. We hypothesised
that renal hyperfiltration is a major determinant of tHcy. To test this hypothesis
we performed renal function tests and measured fasting tHcy levels in 92 type
1 diabetes patients. We also determined the GFR, effective renal plasma flow
(ERPF) and tHcy in 44 control subjects to unravel whether diabetes per se or
the suspected increase in GFR is responsible for the expected decrease in tHcy.
Methods
Ninety two type 1 diabetes patients and 44 control subjects participated in this
study. The type 1 diabetes patients take part in a prospective study of puta-
tive prognostic factors for the development of diabetic nephropathy in which they
will be prospectively followed for up to 15 years. This study describes baseline
data of this study. For type 1 diabetes patients inclusion criteria were: Pres-
ence of type 1 diabetes mellitus according to the criteria of the World Health
Organization 1985: presence of ketosis, low body mass index (BMI) and need
for insulin therapy, age between 18 and 40 years, duration of diabetes between
5 and 12 years, normoalbuminuria (albumin excretion rate < 20 µg·min−1) and
normotension (RR < 140/90 mmHg). Presence of background retinopathy was
accepted. For the type 1 diabetes patients as well as the 44 control subjects ex-
clusion criteria were: macrovascular disease, renal failure (serum creatinine > 150
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µmol·L−1) or liver function abnormalities. The study protocol was approved by
the local medical ethics committee (University Medical Centre Nijmegen St. Rad-
boud, Commissie Mensgebonden Onderzoek) and all participants gave informed
consent. Prior to the renal clearance study, plasma creatinine was measured and
urine was collected for 24 h to estimate GFR. Patients adhered to their usual diet
in the week before the study. Consumption of caffeine containing products was
not permitted in the 24 h prior to the study. All participants were studied in the
morning after a light breakfast. They took a water load of 20 mL·kg−1 and two
intravenous catheters were inserted; one for constant infusion of glucose 2.5% /
NaCl 0.45% (250 mL·h−1) and blood sampling, the other for the constant infu-
sion of p-aminohippurate and inulin adjusted for estimated GFR. After baseline
blood sampling, a priming dose of inulin/p-aminohippurate was given, adjusted
for weight. Thereafter, the continuous infusion of inulin/p-aminohippurate was
started. At 30 minutes intervals blood samples and urine samples were collected.
During the clearance study diuresis was kept above 10 mL·min−1 and urinary
losses over 250 mL·h−1 were replaced by tap water. Glucose was measured regu-
larly and glucose levels were kept between 5 and 10 mmol·L−1 by administering
glucose or insulin when appropriate. Two days after the renal function tests
fasting blood samples were taken for tHcy concentration measurement. Urine
and blood samples were analysed for creatinine, sodium, potassium, chloride,
osmolality, inulin and p-aminohippurate using standard laboratory procedures.
tHcy was measured by a high performance liquid chromatography method as de-
scribed by Fiskerstrand et al. [124] with some modifications. For asessment of
urinary albumin an in-house enzyme-linked immunosorbent assay was used. GFR
was calculated by inulin clearance. ERPF was calculated by p-aminohippurate
clearance. Inulin was purchased from Laevosan, Linz, Austria (Inutest) and p-
aminohippurate from MSD, West Point, PA, USA (Amino Hippurate Sodium).
Statistics For comparison, GFR and ERPF are expressed per 1.73 m2 body sur-
face area (BSA). Correlations between tHcy and the GFR was calculated using
Spearman’s correlation. Differences between groups were calculated with Stu-
dent’s t-test when appropriate, otherwise Mann-Whitney-U -test was used. Dif-
ferences in gender and smoking habits between groups were calculated using the
χ2-test. To test whether differences in tHcy are a consequence of the diabetic
state or are solely determined by differences in GFR, stepwise multiple regression
analysis was performed with sex, albumin excretion rate, HbA1c, GFR and dia-
betic state as independent variables and homocysteine as the dependent variable.
A second multiple regression analysis was performed that included ERPF instead
of GFR.
Results
Characteristics of patients and controls are shown in table 4.1. There was no
significant difference between type 1 diabetes patients and control subjects con-
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Diabetes Patients Controls
(n=92) (n=44)
Age (years) 29.1±6.6 28.5±6.2
Male (%) § 59 52
Smokers (%) 40 30
Body mass index (kg·m−2) 23.3±2.7 22.6±3.0
Duration of diabetes (years) 8.2±2.7 -
Systolic blood pressure (mmHg) 116.3±9.9 115±8
Diastolic blood pressure (mmHg) 62.7±6.9 63.1±6.0
Heart rate (bpm) 65.3±10.8 62.4±10.4
HbA1c (%) ¶ 8.2±1.3 4.9±0.4
Albumin excretion rate (µg·min−1) ¶ 10.1±5.1 7.3±3.5
Creatinine (µmol·L−1) 75±10 76±8
GFR (mL·min−1·1.73m−2) ¶ 121±21 104±14
ERPF (mL·min−1·1.73m−2) ? 563±127 516±121
Plasma total homocysteine (µmol·L−1) † 11.0±4.5 13.7±7
Significant difference between type 1 diabetes patients and control subjects:
? p=0.05; † p=0.01; ¶ p<0.001; § p=0.6
GFR, glomerular filtration rate; ERPF, effective renal plasma flow
Table 4.1: Subject characteristics of diabetes patients and controls
cerning sex, age, BMI, BSA, plasma creatinine, blood pressure and percentage
of smokers. tHcy was significantly lower in type 1 diabetes patients as compared
with control subjects (11.0±4.5 vs 13.4±7 µmol·L−1; p=0.01; figure 4.1).
Patients with diabetes had a higher GFR and ERPF as compared with con-
trols (121±21 vs 104±14 mL·min−1·1.73m−2; p<0.001 and 563±127 vs 516±121
mL·min−1·1.73m−2 p=0.05). Forty-two percent of type 1 diabetes patients had a
GFR in the hyperfiltrating range, when upper 95 percentile of GFR in the control
group was taken for reference [125]. In 5 percent of type 1 diabetes patients the
GFR was above 150 mL·min−1·1.73m−2 [126]. Although all subjects were nor-
moalbuminuric there was a significant difference in albumin excretion rate between
type 1 diabetes patients and control subjects (10.1±5.1 vs 7.3±3.5 µg·min−1 re-
spectively, p<0.001). As expected HbA1c was higher in type 1 diabetes patients
compared to controls (8.2±1.3 vs 4.9±0.4%, p<0.001).
As shown in figure 4.2, both in type 1 diabetes patients and in control subjects
there was a negative significant correlation between tHcy and GFR (type 1 dia-
betes patients: R= -0.43, p<0.001; control subjects: R= -0.39, p=0.01). When
excluding all type 1 diabetes patients and controls with tHcy above 30 µmol·L−1
(n=2 and n=0 respectively), tHcy remained significantly different between type 1
diabetes patients and control subjects (10.5±2.8 vs 13.4±7 µmol·L−1; p=0.01).
Also the significant correlation between GFR and tHcy remained virtually un-
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Figure 4.1: The distribution of plasma total homocysteine for both populations
changed (type 1 diabetes patients: R= -0.43, p=0.005; control subjects: R=
-0.39, p=0.01). GFR and ERPF were not significantly correlated with HbA1c
levels, age or the duration of diabetes. In type 1 diabetes patients, GFR was
significantly correlated with albumin excretion rate (R=0.29, p=0.01). Stepwise
multiple regression analysis (table 4.2) revealed significant independent effects of
sex, GFR and age on tHcy. The presence of the diabetic state was not a predictor
of tHcy.
Discussion
In our large study population of patients with type 1 diabetes and healthy controls
we were able to study the relationship between tHcy and GFR. We found lower
plasma tHcy levels in patients with type 1 diabetes as compared with controls. In
the patients with diabetes as well as the control subjects, tHcy was significantly
correlated with GFR. The lower tHcy in patients with type 1 diabetes can be
explained by the hyperfiltration that is often seen in these patients. Our data
extent the results of previous reports that homocysteine and GFR are inversely
correlated [122]). Most reports thus far are from studies in patients with end
stage renal disease or subjects with a GFR within the normal range. This study
is the first to report a significant correlation in patients with type 1 diabetes,
including patients with relative glomerular hyperfiltration. Glomerular hyperfil-
tration is defined by a GFR above the upper 90 or 95 percentile of non-diabetes
volunteers [125] or GFR above 150 mL·min−1·1.73m−2 [126]. The cause of in-
creased glomerular filtration in type 1 diabetes mellitus remains unclear. There is
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Figure 4.2: Scatterplots of fasting plasma total homocysteine and the glomerular filtra-
tion rate (mL·min−1·1.73m−2)
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β (p-value) β (p-value)
(n=136) (n=136)
Sex 0.22 (0.001) 0.27 (0.002)
Presence of type 1 diabetes mellitus NS -0.25 (0.004)
Albumin excretion rate NS NS
HbA1c NS NS
Age 0.22 (0.01) 0.20 (0.004)
Glomerular filtration rate -0.27 (0.002) -
Effective renal plasma flow - NS
Table 4.2: Stepwise multiple regression models. Effect of selected variables on plasma
total homocysteine. In the left column, glomerular filtration rate is included in the model.
In the right column, the glomerular filtration rate is replaced by the effective renal plasma
flow.
evidence that elevated atrial natriuretic peptide levels contribute to the increased
renal blood flow [127]. Also a high protein diet, which is common in diabetes,
may contribute to an elevated renal blood flow [128]. Metabolic control is often
reported as a potential cause of diabetic hyperfiltration [129]. In our population
we could not find any correlation between long-term glycemic control and the
glomerular filtration rate. The importance of increased glomerular filtration is
stressed by the fact that it is a risk factor for the development of microalbumin-
uria [126; 130–132]. Also in this study there is a positive correlation between
GFR and the albumin excretion rate in patients with type 1 diabetes.
The mechanism by which increased GFR induces reduced tHcy levels is un-
known. Hyperhomocysteinemia is a common finding in patients with renal insuf-
ficiency indicating the importance of the kidney in regulating tHcy levels. About
seventy to eighty percent of tHcy is bound to proteins of high molecular weight.
The remaining 20 to 30% non-protein bound homocysteine consists of homocys-
tine, the disulfide of homocysteine, and mixed disulfides of homocysteine with
other aminoacids like cysteine. About 1% of homocysteine is unbound [133]. The
portion of homocysteine which is bound to small peptides and amino acids and
also unbound homocysteine, is subject to glomerular filtration. This fraction is
freely filtrated and almost completely reabsorbed in the proximal tubules [134]
since loss in the urine is negligible. Besides, inhibitors of tubular resorption like
lysine and arginine seem to inhibit this resorption [135]. After tubular resorption,
this fraction is metabolized into cystathionine or methionine. Studies in rats by
Bostom et al. [136] demonstrated renal extraction of homocysteine by the kidney.
In rats they found a 20% decrease between arterial homocysteine levels and renal
vein homocysteine levels. They also found that urinary excretion of homocysteine
was minimal. One human study by Van Gulderen et al. [137] in which renal artery
and vein sampling was performed, was not able to show any net homocysteine
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extraction by the kidney. The difference between both studies can probably be
explained by higher free plasma homocysteine levels in rats compared to humans
(70 vs 20%). A small renal extraction of homocysteine is hard to detect, as tHcy
determination has a coefficient of variation of about 5%. In contrast to the study
of Van Gulderen et al., our data support the hypothesis that the kidney is an
important organ for elimination of homocysteine.
In summary, the strong correlation between tHcy and the GFR in patients
with type 1 diabetes as well as in healthy controls suggests that renal filtration is
a major determinant of tHcy. In patients with type 1 diabetes tHcy is reduced as
compared with controls. Relative renal hyperfiltration, which is highly prevalent
in patients with type 1 diabetes mellitus is responsible for decreased tHcy as
compared with healthy control subjects.
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Atrial natriuretic peptide and
albuminuria in diabetic patients
Eur J Clin Invest. 2003;33:1026-1027
(Letter)
B.A.J. Veldman
G. Vervoort
J.F.M. Wetzels
i
i
“thesis” — 2009/9/17 — 20:34 — page 38 — #44 i
i
i
i
i
i
38 CHAPTER 5
Sir,
In a previous study published in the European Journal of Clinical Investiga-
tion [2] we reported that atrial natriuretic peptide (ANP) increased albuminuria
in patients with type 1 diabetes mellitus. However, the rise in albuminuria was
accompanied by an increase in the urinary excretion of the low molecular weight
protein β2-microglobulin (β2-m). These observations suggested that the albumin-
uria may at least partly be the result of blockade of tubular protein reabsorption.
However, in our experiments ANP was dissolved in the polygeline Haemaccelr to
prevent adherence of ANP to the synthetic infusion system. We recently became
aware of anecdotal reports that suggested that high dosages of polygelines might
inhibit tubular protein reabsorption [138]. We therefore have questioned our ear-
lier conclusion. We have studied the effect of ANP dissolved in saline instead of
Haemaccelr on urinary excretion of albumin and β2-m in two patients with type
1 diabetes mellitus and a baseline albuminuria of 556 and 382 µg·min−1 respec-
tively. After an equilibration period of 70 minutes, two freely voided urine samples
were collected at 20 minutes intervals. Subsequently, a bolus of 0.06 µg·kg−1 ANP
was given, followed by a continuous infusion of 0.012 µg·kg−1·min−1 ANP. During
ANP infusion three urine samples were collected at 20 minutes intervals. Blood
and urine samples were taken for measurement of creatinine clearance and urinary
excretion of albumin and β2-m. Results are presented in figure 5.1.
Infusion of ANP in saline increased urinary albumin excretion to a similar
extent as ANP in Haemaccelr in our previous study. However, it is evident that
ANP in saline had hardly any effect on urinary β2-m excretion. We have further
confirmed these observation by studying the effects of ANP dissolved in saline
or haemaccelr on urinary albumin and β2-m excretion in healthy volunteers
(see chapter 6, [139]). These data also demonstrate that infusion of ANP does
not increase urinary excretion of β2-m. Therefore, the present study indicates
that increased albuminuria caused by infusion of ANP cannot be explained by
interference of ANP with tubular protein reabsorption. The conclusions of our
previous paper are incorrect. Low doses of polygelines should be avoided in studies
of renal physiology.
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Figure 5.1: Urinary excretion of albumin (top) and β2-microglobulin (bottom) at base-
line and after infusion of atrial natriuretic peptide (ANP). The first pair of bars represent
data from the previous study [2] (ANP in Haemaccelr). The second and third pairs of
bars represent the individual microalbuminuric diabetic patients (ANP in saline).
i
i
“thesis” — 2009/9/17 — 20:34 — page 40 — #46 i
i
i
i
i
i
40 CHAPTER 5
i
i
“thesis” — 2009/9/17 — 20:34 — page 41 — #47 i
i
i
i
i
i
Chapter6
Low concentrations of intravenous
polygelines promote low molecular
weight proteinuria
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Abstract
Background Previously we observed that atrial natriuretic peptide (ANP) in-
duced albuminuria was accompanied by an increase in urinary excretion of the
low molecular weight protein (LMW-protein) β2-microglobulin (β2-m), suggest-
ing that the albuminuria may at least partly be the result of blockade of tubu-
lar protein reabsorption. However, in our experiments ANP was dissolved in the
polygeline Haemaccel® to prevent adhesion of ANP to the infusion system. Anec-
dotal reports have shown that high dosages of polygelines such as Haemaccel®
or Gelofusine® may influence tubular protein handling. In the present study we
have evaluated the effect of a low and high dose of the polygeline Haemaccel®
on proteinuria. In addition, we have reassessed the effects of ANP.
Materials and Methods We have measured urinary β2-m and albumin excretion in
healthy volunteers after infusion of a high dose pure Haemaccel® (0.04 mL·kg−1·
min−1 for 60 minutes), a low dose Haemaccel® (0.01 mL·kg−1·min−1 for 60
minutes followed by infusion of 0.02 mL·kg−1·min−1 for 60 minutes) and a low
dose Gelofusine® (dose comparable to the low dose Haemaccel®). In addition we
have performed similar studies using ANP dissolved in saline and Haemaccel®.
Results Infusion of Haemaccel® caused a dose dependent increase in urinary ex-
cretion of β2-m. There were no differences between Haemaccel® or Gelofusine®.
After infusion of ANP dissolved in Haemaccel® urinary β2-m excretion increased
from 0.05±0.03 µg·min−1 to 27±10 µg·min−1 and urinary albumin excretion in-
creased from 4.5±1.1 µg·min−1 to 9.7±6.3 µg·min−1 (p<0.05). During ANP+sa-
line infusion, urinary β2-m excretion did not change, whereas the urinary albumin
excretion increased from 5.3±1.5 µg·min−1 to 7.9±2.4 µg·min−1 (p<0.05).
Conclusions Our study demonstrates that even low doses of the polygelines Hae-
maccel® or Gelofusine® profoundly attenuate the tubular reabsorption of the
LMW β2-m. ANP does not affect tubular protein reabsorption. Therefore, the rise
in albuminuria during ANP infusion most likely reflects alterations in glomerular
permeability.
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Introduction
Atrial natriuretic peptide (ANP) is a potent natriuretic, diuretic and vasodi-
lating hormone which is predominantly synthetized in mammalian atria [140].
Infusion of ANP provokes albuminuria in healthy subjects, and this albumin-
uric response is even more prominent in patients with hypertension, diabetes or
with non-diabetic renal disease and a nephrotic syndrome [141–144]. Initially, it
was thought that this increase in albuminuria could completely be attributed to
ANP-induced glomerular changes. These changes include an increase in capillary
ultrafiltration coefficient and a characteristic rise in filtration fraction and intra-
glomerular pressure, the latter reflecting the preferential vasodilation of the affer-
ent arteriole and (relative) vasoconstriction of the efferent arteriole [92; 145; 146].
We recently have suggested that blockade of tubular protein reabsorption may be
an important contributing mechanism since we observed a parallel and marked
increase in urinary excretion of the low molecular weight (LMW) protein β2-
microglobulin (β2-m) during ANP infusion [2]. However, in our experiments ANP
was dissolved in the polygeline Haemaccel® to prevent adhesion of ANP to the
infusion system. We recently have confirmed the data of anecdotal reports which
showed that larger amounts of polygelines may influence renal tubular handling
of low molecular weight proteins [138; 147–149]. In our study we have used the
polygeline Gelofusine® [138]. In the present study we have evaluated the effects
of a high dose and a low dose of Haemaccel® on proteinuria. Subsequently we
have compared the effects of two polygelines i.e. Haemaccel® and Gelofusine®.
Finally, we have re-evaluated the effects of ANP on the tubular protein handling
by comparing infusion of ANP either dissolved in saline or in Haemaccel®.
Patients and Methods
Subjects All studies were performed in healthy volunteers recruited from the lo-
cal population. Before inclusion in the study, these subjects were screened for
the absence of hypertension, cardiovascular disease, renal disease and microal-
buminuria. None of them used regular medication, except for the use of oral
contraceptives in some female participants. The use of these oral contraceptives
did not influence any of the parameters measured. The six subjects who partici-
pated in the ANP-studies were measured twice on separate occasions at least one
week apart. In random order they received infusion of ANP in saline on one day
and of ANP in Haemaccel® on an other. The characteristics of the participants
in the separate protocols are shown in table 6.1. The experimental protocols were
approved by the ethics review committee of the University Medical Centre St.
Radboud and written informed consent was obtained from all participants.
Study protocols The evening before the study, the participants ingested 4000 mg
sodium bicarbonate to alkalinise (pH > 6) the urine in order to avoid degrada-
tion of urinary β2-m. They adhered to their usual diet in the days before the
i
i
“thesis” — 2009/9/17 — 20:34 — page 44 — #50 i
i
i
i
i
i
44 CHAPTER 6
Haemaccel Haemaccel Gelofusine ANP study
high dose low dose low dose
Sex (m:f) 1:3 4:2 1:4 3:3
Age (years) 22.8±1.3 24.2±3.6 21±1.4 24.5±2.6
Height (m) 1.73±0.1 1.81±0.1 1.72±0.1 1.75±0.1
Weight (kg) 72±10 77±19 70±11 65±8
BSA (m2) 1.87±0.2 1.96±0.3 1.83±0.3 1.78±0.1
BMI (kg·m−2) 24±2 23±3 24±2 21±3
Values are expressed as means±SD.
Table 6.1: Baseline characteristics of study participants. BSA, body surface area; BMI,
body mass index [weight/(height)2].
study but were instructed to abstain from alcohol, caffeine and nicotine for at
least 12 h before the experiments. All participants were admitted to the clini-
cal research centre at 8.00 a.m after they had eaten a light breakfast. Subjects
did not ingest any other food until the study was completed. After arrival, they
consumed an oral water load of 20 mL·kg−1 and two plastic cannulas were in-
serted into an antecubital vein of each arm, one infusion and the other for blood
sampling. In all studies basal infusion consisted of glucose/NaCl at a rate of 250
mL·h−1. In order to achieve a steady-state urinary output, urinary losses (over
250 mL·h−1) were replaced by drinking tap water. All subjects remained supine
throughout the study but were allowed to stand to urinate. After an equilibration
period of 70 min, in which the urine output reached values of 10 mL·min−1 or
more, three freely voided urine samples were collected at carefully timed inter-
vals. The average of the two last collections served as baseline. Blood samples
were taken before and after each urine collection period. After obtaining base-
line values, the further protocol was different between the studies. To confirm our
earlier results of high dose Gelofusine® induced low molecular weight (LMW) pro-
teinuria, we administered a high dose of Haemaccel® (Hoechst, Behring-Werke,
Marburg Germany, concentration 35 g·L−1) intravenously (bolus: 0.1 mL·kg−1
followed by infusion of 0.04 mL·kg−1·min−1 for 60 min). Urine was collected
at 20 min intervals and blood samples were again taken before and after each
collection period. In a subsequent study, we investigated whether polygeline in-
duced LMW-proteinuria was dose dependent, by infusion of a lower dose of pure
Haemaccel®. After a bolus injection of 0.05 mL·kg−1, Haemaccel® was infused
for 60 min at a rate of 0.01 mL·kg−1·min−1, thus providing a total amount of
approximately 1 g of Haemaccel® for an average 70 kg subject. Thereafter, a
second bolus injection of 0.1 mL·kg−1 was given and the infusion was continued
at a rate of 0.02 mL·kg−1·min−1 for 60 min. Urine was collected at 30 min
intervals and blood samples were again taken before and after each collection
period. To investigate whether the effect on the excretion of the LMW-protein
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β2-m was polygeline specific, we administered Gelofusine® (Braun NPBI Oss,
the Netherlands, concentration 40 g·L−1), another polygeline, at a rate of 0.01
mL·kg−1·min−1, after a bolus injection of 0.05 mL·kg−1. Thereafter, a second
bolus injection of 0.1 mL·kg−1 was given and the infusion was continued at a
rate of 0.02 mL·kg−1·min−1 for 60 min. Urine was collected at 30 min intervals
and blood samples were again taken before and after each collection period. In
the ANP-study, ANP infusion followed the baseline measurements. ANP was dis-
solved in saline or in Haemaccel®. Taking into account an estimated loss of 20%
of ANP when dissolved in saline, we adjusted the concentration of the solutions
so that the effective ANP dose was equal in both experiments. The final concen-
tration of ANP in Haemaccel® and in saline was 1 µg·mL−1 and 1.2 µg·mL−1
respectively. After a bolus of 0.05 mL·kg−1·min−1, ANP was infused at a rate
of 0.01 mL·kg−1·min−1 for 60 min. Urine was collected at 20 min intervals and
blood samples were again taken before and after each collection period. In all
studies creatinine clearance was used as a marker of GFR. To allow formal com-
parison with our earlier study using ANP [2] in the ANP protocols we also have
measured inulin and PAH clearance as markers of GFR and ERPF respectively.
During all four studies blood pressure was measured at 10 min intervals during
each collection period with an automatic oscillometric device (Dinamap, 1846 SX,
Critikon, Tampa, Florida, USA). Urine and blood samples were analyzed for crea-
tinine, sodium, potassium, osmolality, inulin and PAH using standard laboratory
procedures. Urine samples for the determination of albumin and β2-m were stored
at -80. Urinary excretion of albumin and β2-m were determined with an ELISA
as previously described [2]. ANP-(99-126) was purchased from Clinalfa, Lauflin-
gen, Switzerland. Inulin was purchased from Laevosan, Linz, Austria (Inutest®)
and PAH from MSD, West Point, PA, USA (Amino Hippurate Sodium). In the
ANP-studies, plasma concentration of ANP in blood was determined just before
the start of ANP infusion (baseline) and at the end of the clearance study, and
was measured by a radioimmunoassay as previously described [100].
Calculations Urinary clearance of a substance (Cx) was calculated with the stan-
dard formula :
Ux × VPx
where U = urinary concentration of substance x, V = urinary flow rate and P
= plasma concentration. The clearances of inulin (ANP studies) and creatinine
(polygeline studies) were used as markers of the glomerular filtration rate (GFR).
The clearance of PAH was used as a marker of the effective renal plasma flow
(ERPF) (ANP studies). The filtration fraction was calculated as GFR/ERPF.
Fractional excretions were calculated as clearance of a substance divided by GFR.
Statistical analysis Parameters before and after the infusion of ANP were analysed
by paired Student’s t-test for normally distributed data or Wilcoxon’s signed rank
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test for non-parametric data. A p-value < 0.05 was considered to be the level
of statistical significance. Unless otherwise indicated, values are expressed as
means±SD.
Results
Effects of polygeline infusion The infusions were carried out without complications
and data collection was complete. Infusion of Haemaccel® or Gelofusine® did
not affect blood pressure, haematocrit, ECC, urinary water and sodium excretion
(data not shown). The effects of Haemaccel® and Gelofusine® on the urinary
excretion of albumin and β2-m are presented in figure 6.1. During the infusion
of the polygelines, a rapid and significant increase (p<0.001) in absolute and
fractional β2-microglobulin excretion was observed, whereas the excretion rate of
albumin remained unaltered. Infusion of the higher dose of Haemaccel® resulted
in a significantly higher urinary excretion of β2-m than observed with the lower
doses. We did not observe any differences between Gelofusine® or Haemaccel®.
Effects of ANP+saline and of ANP+Haemaccel® infusion No symptoms were experi-
enced by the volunteers and the infusion of ANP had no significant influence on
blood pressure or pulse rate. Plasma ANP levels rose significantly (p<0.001)
and to the same extent during the infusion of either ANP solution (ANP+saline:
9.4±1.2 nmol·L−1 to 47.1±11.6 nmol·L−1; ANP+Haemaccel®: 7.6±2.0 nmol·L−1
to 55.6±25.0 nmol·L−1; both: p<0.001). The effects of ANP infusion on renal
haemodynamics are shown in figure 6.2.
With both ANP solutions, the ERPF (Panel A) tended to decrease whereas
the GFR (Panel B) tended to increase, although the changes did not reach sta-
tistical significance. As a result, the filtration fraction increased from 0.20±0.03
to 0.24±0.02 during ANP+saline (p<0.001) and from 0.19±0.01 to 0.23±0.02
during ANP+Haemaccel infusion (p<0.001). The infusion of ANP did not sig-
nificantly alter the urinary flow rate (data not shown). Fractional sodium ex-
cretion increased from 1.36±0.56% to 2.36±0.64% during ANP+saline, and from
1.82±0.83% to 2.50±0.48% during ANP+Haemaccel®. Both studies were com-
parable with respect to the absolute and percentage changes of ERPF, GFR,
filtration fraction, fractional sodium excretion and urinary flow rate. Major dif-
ferences were observed with respect to the excretion of urinary proteins (figure
6.3).
During infusion of ANP+Haemaccel®, the urinary β2-m excretion (Panel A)
increased significantly from 0.05±0.03 µg·min−1 to 27.1±10.4 µg·min−1 (p<0.001)
and urinary albumin excretion (Panel B) increased from 4.5±1.1 µg·min−1 to
9.7±6.3 µg·min−1 (p<0.05). During ANP+saline infusion, the urinary β2-m ex-
cretion did not change significantly, whereas the urinary albumin excretion in-
creased from 5.3±1.5 to 7.9±2.4 µg·min−1(p<0.05).
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Figure 6.1: Effects of infusion of high dose Haemaccelr and low dose Haemaccelr and
Gelofusiner on urinary β2-microglobulin excretion (upper panel) and albumin (lower
panel). Values are given as means±SD. ??p<0.001 compared with basal values.
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Figure 6.2: Renal haemodynamics before (baseline) and after the infusion of atrial
natriuretic peptide (ANP) in saline(◦) and in Haemaccelr (). (a) Effective renal
plasma flow (ERPF). (b) Glomerular filtration rate (GFR). (c) Filtration fraction (FF).
(d) Fractional excretion of sodium (FENa). Values are given as means±SD. The changes
in ERPF, GFR and FF were similar during both infusions. Filtration fraction increased
significantly during either infusion (??p<0.001; ?p<0.01)
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Figure 6.3: Effects of infusion of atrial natriuretic peptide (ANP) in Haemaccelr
() and saline(◦) on urinary excretion of (a) β2-microglobulin and (b) urinary albumin
excretion. Values are given as means±SD. ??p<0.001 compared with baseline values.
?p<0.05 compared with baseline values.
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Discussion
The results of this study clearly indicate that the infusion of a dose as low as 0.75
mL·min−1 (1.8 g·h−1) of the polygeline Haemaccel® can substantially increase
the urinary excretion of β2-m, without affecting the renal excretion of albumin.
Our data clearly show that this effect is dose dependent. Furthermore, we did not
observe any difference between two preparations tested here (i.e. Haemaccel®
and Gelofusine®). Taken together our study confirms and extends previous ex-
periments which showed a profound effect of the infusion of larger amounts (10
to 17.5 g) of polygelines on the renal excretion of low molecular weight proteins
[138; 147]. The increased excretion of β2-m during Haemaccel® infusion is most
likely the consequence of a competitive inhibition of tubular protein reabsorption.
LMW-proteins such as β2-m are freely filtered in the glomerulus with a sieving
coefficient approximating 1.0, and effectively reabsorbed by the renal proximal
tubules. Therefore, the huge increase in urinary β2-m excretion must be explained
by interference with the tubular reabsorption process. Haemaccel® is a synthetic
polymer of partially degraded gelatin. Beetham et al. [147] performed a gel filtra-
tion of the preparation and demonstrated that it contains a significant proportion
of degradation products of less than 35 kD molecular weight. This low molecular
weight fraction rapidly undergoes glomerular filtration and appears in the urine.
Even with a low dose of 1 g the concentration in the tubular fluid will be around
20-50 mg·L−1, much higher than the concentration of β2-m. Therefore, Beetham
et al. previously suggested that Haemaccel® inhibits tubular binding of other
low molecular weight proteins simply by virtue of its higher tubular concentra-
tion. Notably, the effect is somewhat protein specific since we did not observe an
increase in urinary excretion of albumin, a protein that is also reabsorbed to some
extent by the proximal tubule. Polygelines like Haemaccel® and Gelofusine® are
frequently used in clinical practice as plasma expanders. The inhibition of tubular
reabsorption of LMW-proteins by polygelines can lead to spurious interpretation
of results. LMW-proteinuria in patients who have received polygelines does not
necessarily indicate tubular damage, but can be merely the result of inhibition of
tubular reabsorption.
The results of our second set of experiments are also clear: ANP when dis-
solved in saline does not affect proximal tubular protein handling. The increased
albuminuria that occurs after infusion of ANP must be the result of alterations
in glomerular permeability. The increased excretion of β2-m that we observed
in our previous experiments is fully explained by the use of low concentration of
Haemaccel®. Admittedly, other investigators have also reported a significant rise
in urinary β2-m excretion after ANP infusion [141; 150]. In these latter studies
ANP was dissolved in saline. We feel that these apparent discrepancies in study
results are most likely explained by differences in study protocol. One impor-
tant issue is the effect of urinary flow rate on urinary protein excretion. This
issue was addressed in a study by Jung et al. who demonstrated an increased
urinary excretion rate of the low molecular weight protein β2-m after induction
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of a firm diuresis by a fluid load of 22 mL·kg−1 body weight [151]. The authors
felt supported by our finding that total protein excretion is influenced by urinary
flow rate [152]. However, our results did not correspond with those of Jung et
al. because we found that urinary protein is constant and independent of diuresis
at urinary flow rates above 1.5 mL·min−1 [153]. We believe that the contrasting
observations by Jung et al. can be explained by the fact that the investigators
did not avoid excessive hydration and rapid changes in urinary volume which
may have led to the washout of urinary dead space, resulting in high excretion
rates of low molecular weight proteins, as has clearly been demonstrated for cre-
atinine and for albumin [154; 155]. A similar pattern of a transient increase in
the excretion of low molecular weight proteins may be involved in the studies by
Semmekrot et al.[150] and by Eiskjær et al.[141]. In this context, it should be
noted that in both studies very high doses (1 µg·kg−1 to 2 µg·kg−1) of ANP were
administered as bolus injections, resulting in rapid changes in urinary flow rates.
In addition, these high ANP dosages induced changes in systemic haemodynam-
ics which may have interfered with tubular protein handling. The ANP dose
used in our study was chosen to increase albuminuria, with minimal effects on
systemic haemodynamics. Eiskjær and Pedersen [156] studied the dose-response
relationship of ANP on (renal) haemodynamics. Compared to placebo, a bolus
injection of 0.5 µg·kg−1 did not significantly alter GFR, ERPF or urinary flow
rate. In a dose-dependent manner, increasing doses of ANP (up to 2 µg·kg−1) in-
creased urinary sodium excretion, GFR, pulse rate and urinary flow rate reaching
a plateau at the highest ANP doses. ERPF and mean arterial pressure decreased
dose-dependently reaching a plateau at the highest ANP doses. In an animal
study, Blaine et al. [157], reported a bell shaped dose-response relationship with
regard to urinary sodium excretion in respons to ANP infusion. Our cumulative
ANP dose was chosen below 0.5 µg·kg−1· As shown the ANP dose used in our
study increased albuminuria significantly. In another study by Eiskjær et al.[141],
the excretion of β2-m rose by 655% in patients with essential hypertension. It is
thereby noteworthy that the abrupt changes in urinary flow after ANP injection
were much more pronounced in these hypertensive patients (from 7.0 mL·min−1
to 15.3 mL·min−1) compared to the normotensive controls (from 7 mL·min−1 to
11 mL·min−1). In the latter control group β2-m excretion increased only by 60%
which is comparable to the changes in our experiments and in another study by
Mc Murray et al. [142]. Nevertheless, these changes reached the level of statistical
significance in the study by Eiskjær et al. whereas this was not the case in the
present study and in the study by Mc Murray et al. Taken together, these ob-
servations suggest that the increased β2-m excretion during ANP rather reflects
rapid fluctuations in urinary flow rate and changes in systemic haemodynamics
than alterations of proximal tubular protein reabsorption.
In conclusion, our data clearly indicate that a low dose of the polygeline
Haemaccel® profoundly affects tubular reabsorption of the low molecular weight
protein β2-microglobulin. ANP when dissolved in saline increases urinary albumin
excretion without affecting the urinary excretion of β2-microglobulin. Therefore,
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the rise in albuminuria during ANP infusion most likely simply reflects changes
in glomerular permeability.
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Abstract
Background The endothelial nitric oxide synthase Glu298Asp polymorphism has
been suggested to play a role in the development of hypertension, atherosclerosis
and coronary artery disease.
Aim To investigate functional differences between the various genotypes with
respect to basal NO production, we estimated the response to ecNOS inhibition
by infusion of increasing doses of L-NMMA into the brachial artery during venous
occlusion plethysmography.
Methods In 41 healthy subjects forearm blood flow responses to intra-arterial
infusion of increasing doses of L-NMMA (0.05, 0.1 and 0.2 mg·min−1·dL−1) and
norepinephrine (10, 20 and 40 ng·min−1·dL−1) were measured. The genotype of
the ecNOS Glu298Asp polymorphism was assessed.
Results Nineteen subjects had the Glu/Glu genotype, 19 subjects had the Glu
/ Asp genotype and 3 subjects had the Asp/Asp genotype. Groups were compa-
rable concerning demographic, haemodynamic and possible confounding factors.
Subjects with the Asp allele showed a reduced response to infusion of L-NMMA
as compared with subject with the Glu/Glu genotype (ANOVA, p=0.01). There
was no significant difference in the response to infusion of the NO independent
vasoconstrictor norepinephrine between both groups.
Conclusions The ecNOS Glu298Asp polymorphism is associated with reduced
basal NO production and might therefore have functional implications in the
development of atherosclerosis or hypertension.
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Introduction
Endothelium derived nitric oxide (NO) is an important regulator of vascular tone.
Besides its potent vasodilator capacity, NO inhibits vascular smooth muscle cell
migration [158] and growth [159], inhibits endothelial adhesion of leucocytes and
thrombocytes [160; 161] and limits the oxidation of low-density lipoproteins [162].
Because of these properties, a reduced bioavailability of NO may play a role in
the development or progression of hypertension, atherosclerosis and other vascular
diseases. The importance of NO in vascular function is stressed by several studies.
Knock-out mice lacking the ecNOS gene become hypertensive and inhibition of
ecNOS elevates blood pressure in non-hypertensive humans [163].
As it becomes more clear that genetic factors play a role in cardiovascular
disease, it is tempting to assume a role for polymorphisms of the ecNOS gene
in the susceptibility to develop cardiovascular disease. NO is produced from the
amino acid L-arginine by the enzyme NOS. Several iso-forms of the enzyme ex-
ist of which endothelial NO synthase (ecNOS) is expressed in the endothelium.
EcNOS is encoded by the NOS 3 gene on chromosome 7. Recently, several poly-
morphisms of the ecNOS have been identified. Of these, the G894T nucleotide
polymorphism seems clinically relevant as it leads to an amino acid substitution
at the 298 location of the ecNOS gene: Glu298Asp (glutamic acid substituted
by aspartic acid) [164]. Although some investigators have suggested that the
Glu298Asp polymorphism is associated with an increased incidence of hyperten-
sion, functional in-vivo data on this issue are scarce [165]. We hypothesize that
differences in the genotype of ecNOS may be reflected by differences in the base-
line release of NO from the endothelium. To address this hypothesis, we estimated
the differences in basal NO production between the different genotypes of the ec-
NOS Glu298Asp polymorphism in a group of healthy volunteers, by quantifying
the vasoconstrictor response to ecNOS inhibition by infusion of NG -monomethyl-
L-arginine (L-NMMA) into the brachial artery.
Methods
We recruited 41 healthy subjects from the local community. All subjects fulfilled
the following criteria: age between 18 and 40; blood pressure (BP) < 140/90
mmHg, no antihypertensive medication and no signs of cardiovascular disease.
Since primary hypertension and atherosclerosis have been associated with an im-
paired vasoconstrictor response to L-NMMA theses subjects were excluded. All
subjects signed the informed consent and the study protocol was approved by the
local medical ethical committee.
Subjects were instructed to abstain from alcohol and caffeine for 24 h and
refrain from smoking 12 h before the study. The study was performed between
8.00-12.00 a.m. All subjects attended the clinic after an overnight fast. Fifteen
minutes after cannulation of the brachial artery of the non-dominant arm, intra-
arterial blood pressure was recorded for 5 min. Thirty minutes after cannulation,
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arterial blood samples were collected for DNA extraction. Further, blood sam-
ples were taken for evaluation of all kind of potential confounding factors which
may affect endothelial function: cholesterol, homocysteine, insulin, glucose, gly-
cosylated haemoglobin (HbA1c), and catecholamines. Thereafter, forearm blood
flow (FBF) was measured by venous occlusion strain gauge plethysmography as
described before [166]. After assessment of the baseline FBF, increasing doses of
the NOS inhibitor L-NMMA (0.05, 0.1 and 0.2 mg·min−1 per dL forearm vol-
ume [mg·min−1·dL−1]) were infused into the brachial artery. After each infusion
period of five minutes for the respective doses, the effect of the infusion of L-
NMMA on FBF was measured by venous occlusion plethysmography in the final
two minutes. As L-NMMA blocks NO synthase, the fall in FBF can be consid-
ered as a measure of the baseline production of endothelial NO. After a 60 minute
equilibration interval, FBF was returned towards baseline levels. Subsequently
increasing doses of norepinephrine (10, 20, 40 ng·min−1·dL−1) were infused into
the brachial artery. Measurements of FBF was performed as described above.
Norepinephrine was used as an endothelial independent vasoconstrictor agent to
rule out non-specific vascular responses in the Asp allele group.
DNA was extracted from whole blood using the QIAamp Blood Kit (Qiagen,
Inc.). Genotyping of the ecNOS Glu298Asp polymorphism was performed using
a multilocus genotyping assay for candidate markers of cardiovascular disease risk
[167] (Roche Molecular Systems, Inc.). Briefly, each DNA sample is amplified us-
ing two multiplex polymerase chain reactions, and the alleles are genotyped simul-
taneously using an array of immobilised, sequence-specific oligonucleotide probes.
This array of probes is blotted on plastic strips and after staining, genotypes can
be scored based on blue (positive) and white (negative) bands. Each blue band,
representing a specific genotype, was scored by specific software (counting the
pixel intensity of each band) and manually checked. Insulin was measured with
an insulin-specific double antibody RIA (interassay CV 6.2%). Plasma glucose
was measured using a standard glucose oxidation method. HbA1c was measured
using a HPLC technique (Bio-Rad Diamattm, the Netherlands) with reference
values of 4.8-6.2%. Plasma cathecholamines were measured using a highly sensi-
tive and specific HPLC technique [168]. Homocysteine was measured by a high
performance liquid chromatography method as described by Fiskerstrand et al.
[124] with some modifications. Plasma cholesterol and triglyceride concentrations
were determined by commercially available enzymatic reagents. HDL-cholesterol
was determined with the polyethylene glycol 6000 method [169]. Free fatty acids
were measured using an enzymatic colorimetric method (ACS-ACOD method,
Wako Chemicals, Neuss, Germany).
Due to expected small numbers in the Asp/Asp genotype group, this group
was combined with the Glu/Asp group in the statistical analyses to form the
Asp allele group (Glu/Asp and Asp/Asp). Genetic analysis was performed after
the plethysmography studies, so the investigators performing these studies were
blinded for the genotypes of the subjects. Results are presented as means±SD
unless indicated otherwise. FBF is expressed in mL·min−1 per dL of forearm
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Figure 7.1: Mean response (±SEM) to infusion of increasing doses of L-NMMA and
norepinephrine in both genotype groups (?p<0.05; ??p<0.01).
tissue (mL·min−1·dL−1). Delta FBF is calculated by subtracting the measured
flow during infusion of study medication from the FBF at baseline. The per-
centage change in FBF (∆%FBF) is calculated as the difference between FBF
at baseline and FBF during infusion of study medication, divided by the FBF
at baseline. Mann-Whitney-U test was used to test for significant differences in
non-parametric variables, otherwise, Student’s t-test was used. Differences be-
tween groups in dose/response on infusion of L-NMMA and norepinephrine were
tested using ANOVA for repeated measures. Differences in smoking habits and
sex between the various genotypes were tested for significance using the χ2 test.
Differences were considered to be significant at p-values below 0.05.
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Glu/Glu Glu/Asp + Asp/Asp
genotype genotype
(n=19) (n=22)
Demographics
Gender (male:female) 11:8 10:12
Age (years) 29.7±4.9 28.7±7.0
Smoking (y/n) 4/15 6/16
Body mass index (kg·m−2) 22.7±2.3 22.8±3.7
Haemodynamics
Systolic blood pressure (mmHg) 116.0±9.4 115.6±7.1
Diastolic blood pressure (mmHg) 64.7±6.4 62.1±5.6
Pulse pressure (mmHg) 51.2±5.4 53.5±6.6
Heart rate (bpm) 63.2±11.4 61.7±10.0
Possible confounders
Total serum cholesterol (mmol·L−1) 4.4±1.1 4.2±1.0
LDL-cholesterol (mmol·L−1) 2.77±1.06 2.49±1.10
HDL-cholesterol (mmol·L−1) 1.23±0.31 1.15±0.24
Triglycerides (mmol·L−1) 1.15±1.2 1.01±0.90
Free fatty acids (mmol·L−1) 0.42±0.16 0.38±0.13
Homocysteine (µmol·L−1) 11.9±3.9 13.5±4.8
Glucose (mmol·L−1) 5.2±0.38 5.1±0.35
HbA1c (%) 5.0±0.3 4.9±0.5
Insulin (pmol·L−1) 8.0±3.8 7.6±2.8
Epinephrine (nmol·L−1) 0.21±0.14 0.22±0.17
Norepinephrine (nmol·L−1) 0.86±0.37 0.77±0.38
Values: means±SD.
LDL, low-density lipoprotein; HDL, high-densitiy lipoprotein.
Table 7.1: Clinical characteristics of the Glu/Glu genotype and the combined Glu/Asp
and Asp/Asp genotype
Results
Nineteen subjects (46%) had the homozygous wild type (Glu/Glu) genotype, 19
(46%) had the heterozygote (Glu/Asp) genotype and 3 subjects (7%) had the
homozygous mutant (Asp/Asp) genotype. The observed genotype frequencies
were in Hardy-Weinberg equilibrium. As shown in table 7.1 there were no signifi-
cant differences between the wild type group (Glu/Glu) and the Asp allele group
(Glu/Asp and Asp/Asp) concerning age, sex, smoking habits, body mass index,
blood pressure, heart rate and all possible confounding factors such as stated in
table 7.1.
There was no significant difference in basal FBF between the two groups
(Glu/Glu vs Glu/Asp and Asp/Asp: 2.1±0.7 resp. 2.1±0.6 mL·min−1·dL−1).
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Glu/Glu Glu/Asp + Asp/Asp
genotype genotype
(n=19) (n=22)
Absolute FBF (mL·min−1·dL−1)
FBF at baseline 2.07±0.66 2.06±0.63
FBF at first dose of L-NMMA 1.72±0.63 1.76±0.70
FBF at second dose of L-NMMA 1.47±0.52 1.66±0.66
FBF at third dose of L-NMMA 1.31±0.49 1.57±0.66
Change in FBF (mL·min−1·dL−1)
∆FBF at first dose of L-NMMA -0.34±0.18 -0.30±0.33
∆FBF at second dose of L-NMMA -0.60±0.23 -0.40±0.28∗
∆FBF at third dose of L-NMMA -0.76±0.25 -0.49±0.38∗
Percentage change in FBF (%)
∆%FBF at first dose of L-NMMA -17.7±10.1 -15.3±13.5
∆%FBF at second dose of L-NMMA -29.3±8.0 -20.6±14.1∗
∆%FBF at third dose of L-NMMA -37.1±7.8 -24.9±18.6∗∗
Values: means±SD. ∗p < 0.05, ∗∗p < 0.01.
L-NMMA, NG -monomethyl-L-arginine.
Table 7.2: Results of forarm blood flow (FBF) measurement at baseline and during the
infusion of increasing doses of L-NMMA.
The highest dose of L-NMMA induced an absolute fall in FBF which was less pro-
nounced in the mutant group as compare with the wild type group (-0.49±0.38 vs
-0.76±0.25 mL·min−1·dL−1; p=0.02) (table 7.2). Also the percentage decrease in
FBF (∆%FBF) was significantly less in mutants as compared with wild type ho-
mozygotes (-25±19 vs -37±7.8%; p=0.02) (table 7.2). When testing for differences
in the complete dose-response curve between mutants and wild type homozygotes,
the mutant group showed a blunted response on infusion of L-NMMA as compared
with the wild type group (ANOVA for repeated measures: p=0.01. See figure 7.1).
The ∆FBF was significantly lower in the mutant group (Glu/Asp and Asp/Asp)
as compared with the wild-type homozygotes (ANOVA fore repeated measures,
p=0.02. See figure 7.1). The percentage of change in FBF (∆%FBF) was also
significantly lower in the mutant group as compared with wild-type homozygotes
(ANOVA for repeated measures, p=0.03. See figure 7.1). Throughout the exper-
iment the FBF in the control arm did not change significantly.
The response to intra-arterial infusion of norepinephrine was not significantly
different between groups, neither for the absolute values of FBF, nor for the
absolute or percentage changes in FBF (see figure 7.1).
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Discussion
In this study we investigated the functional significance of the ecNOS Glu298Asp
polymorphism as far as the baseline endothelial release of NO is concerned. This
study is the first to report that the presence of an Asp allele of the ecNOS
Glu298Asp polymorphism is associated with a reduced basal NO production. The
absolute and relative decrease in FBF during infusion of L-NMMA was attenu-
ated in the Asp variant of the ecNOS Glu298Asp polymorphism as compared with
the Glu variant. There was no significant difference between genotype groups
concerning the response to intra-arterial infusion of norepinephrine. As nore-
pinephrine induces endothelium-independent vasoconstriction, this indicates that
the observed difference between the genotypes can be attributed to differences in
the NO-pathway. NO is a potent vasodilator, and the basal NO production by
the endothelium is a major determinant of basal flow. As NO has a short half-
life, basal NO concentrations are highly dependent on continuous synthesis from
L-arginine by NOS. When blocking NO production by means of L-NMMA, the
absolute decrease in blood flow is a reflection of the basal NO production by NOS
[170; 171]. In this study we report that subjects with the Asp allele of ecNOS
showed an attenuated fall in FBF on infusion of L-NMMA. This indicates that the
basal NO production in subjects with the mutant variant of the ecNOS gene is
reduced as compared with the wild type. In theory, this observation may under-
lie the reported statistical relation between ecNOS gene polymorphisms and the
presence of hypertension or cardiovascular disease. Studies evaluating the associ-
ation of the ecNOS Glu298Asp polymorphism in the development of hypertension
reveal conflicting results. Miyamoto et al. [172] reported an increased Asp/Asp
genotype frequency in Japanese hypertensive patients. Lacolley et al. [173] on
the contrary, reported increased Glu/Glu genotype frequency in hypertensive sub-
jects. Moreover, a study by Kato et al. [164] was not able to find any significant
difference in allele frequencies between hypertensive patients and control sub-
jects. Hingorani et al. [174] and Yoshimura et al. [175] reported an increased risk
for the development of coronary artery disease in Asp/Asp homozygotes. One
negative linkage study of the ecNOS Glu298Asp polymorphism in hypertensive
patients [164] does not rule out a functional impairment of the Asp allele, because
the level of NO inhibition required to induce atherosclerosis does not necessar-
ily cause systemic hypertension [176]. Therefore, if the Asp allele causes only
slight reductions in basal NO production, this might promote the development
of atherosclerosis and endothelial dysfunction without directly affecting systemic
blood pressure. In our study population, no significant differences in blood pres-
sure were found between the various genotypes. Studies on NOS polymorphism
which focussed on the occurrence of atherosclerotic events as end-points are in
line with this reasoning [164; 174]. Recently Schneider et al. [165] reported that
the Asp allele of the Glu298Asp polymorphism of the ecNOS gene was not associ-
ated with reduced basal NO production. Using exactly the same technique as we,
they first estimated the response to infusion of acetylcholine, after which sodium
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nitroprusside (SNP) and L-NMMA were infused. They did not find any differ-
ence between the various genotypes in response to infusion of acetylcholine, SNP
and L-NMMA. However, the study design of Schneider et al. was not appropri-
ate for assessment of the baseline NO production. We have previously published
that the vasoconstrictor response to L-NMMA-infusion is augmented after pre-
infusion of acetylcholine as compared with baseline [177]. So, it is not possible to
quantify baseline NO release appropriately after first stimulating NO release by
intra-arterial infusion of acetylcholine [178]. Therefore, on the basis of the results
of Schneider et al. [8], it is not possible to draw any conclusion concerning func-
tional consequences of the Glu298Asp polymorphism of the ecNOS gene as far as
the baseline production of NO is concerned. In contrast, our study only focussed
on baseline production of NO since we started the experiments with infusion of
L-NMMA.
The allele frequencies of the ecNOS Glu298Asp polymorphism found in this
study are comparable with those reported in other studies in European subjects
[173; 174; 179]. These studies report homozygosity for the Asp allele in approxi-
mately 10% of the study population. Three Japanese studies [164; 172; 175] found
a combined homozygous and heterozygous frequency for the Asp allele in approx-
imately 10-15% of healthy subjects. This marked difference in allele frequencies
of the ecNOS Glu298Asp polymorphism may suggest that their study population
had a genetically different background compared to the other studies.
Even though we found a marked difference in basal NO production between
the various genotypes, basal blood flow itself was not different among the groups.
This suggests that other mechanisms compensate for the decreased basal NO
production.
In conclusion, the Glu298Asp polymorphism of the ecNOS gene seems to be
functionally relevant as decreased amounts of basal NO production are found in
healthy subjects that are heterozygous or homozygous for the Asp allele of this
polymorphism.
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Abstract
Background L-NMMA is widely used in venous occlusion plethysmography stud-
ies to determine baseline NO production. Studies using L-NMMA indicate that
endothelial dysfunction is present early in the course of diabetic microvascular
complications. However, the optimal dose to maximally inhibit NO-production is
unknown.
Objective To determine the L-NMMA-dose that maximally reduces basal forearm
blood flow (FBF). To investigate whether there are any differences in the response
to L-NMMA between non-complicated type 1 diabetes patients and control sub-
jects.
Methods In 8 non-complicated type 1 diabetes patients and 9 healthy subjects
FBF-responses to intra-arterial infusion of increasing doses of L-NMMA (0.01-
1.6 mg·min−1·dL−1 forearm volume [FAV]) were measured using the perfused
forearm technique.
Results Infusion of 0.8 mg·min−1·dL−1 maximally reduced FBF. The dose of
1.6 mg·min−1·dL−1 did not additionally reduce FBF. No differences existed be-
tween non-complicated type 1 diabetes patients and controls with regard to EC50
(0.017±0.02 vs 0.22±0.02 mg L-NMMA·min−1·dL−1) or maximal vasoconstric-
tive response (∆FBF: 1.13±0.4 vs 0.97±0.4 mL·min−1·dL−1). Throughout the
study blood pressure increased significantly in both groups, possibly reflecting a
systemic vasoconstrictive effect of L-NMMA.
Conclusions The maximal vasoconstrictive dose was 0.8 mg·min−1·dL−1 in type
1 diabetes patients as well as the control subjects. There were no significant
differences between non-complicated type 1 diabetes subjects and controls with
regard to the pharmacodynamics of L-NMMA. At high dosages of L-NMMA a
systemic effect can not be ruled out.
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Introduction
In the past decades, the endothelial release of nitric oxide (NO) has been shown to
be one of the key regulators of baseline vascular tone. In patients with atheroscle-
rosis and in those with cardiovascular risk factors like hypertension and hyper-
cholesterolemia, dysfunction of this NO pathway is a common finding. In non-
complicated diabetes mellitus, however, observations on this specific issue are still
controversial. The literature varies from reports on an impaired [180; 181] an un-
altered [65; 182], or even an increased release or action of NO in non-complicated
diabetes mellitus [70]. The optimal method to assess the contribution of NO to
baseline vascular tone is to quantify the vasoconstrictor response to specific block-
ade of endothelial NO-synthase. In humans, this is almost exclusively done by the
infusion of the NO-synthase blocker NG-monomethyl-L-arginine (L-NMMA) into
the brachial artery using the perfused forearm technique [166; 183]. This is a very
elegant technique because of its local character thereby avoiding the administra-
tion of systemic dosages. An important shortcoming in the forearm studies so far
is the relative low dose of L-NMMA which is not sufficient for a complete block-
ade of NO-synthase. Up to now, dosages did not exceed 0.4 mg·min−1 per dL
of forearm tissue (or 4 mg·min−1 in total, equivalent to ±16 µmol·min−1), and
at this dose a maximal vasoconstrictor response to L-NMMA was not achieved
[180; 182; 184; 185]. As such, an accurate assessment of the contribution of NO
to baseline vascular tone is missing in the current literature, both in healthy vol-
unteers as well as in type 1 diabetes patients. The aim of the present study is
to perform complete concentration response curves for L-NMMA by use of the
perfused forearm technique. Subsequent fitting of these concentration-response
curves according to the sigmoid E-max model will enable us to calculate the EC50
and the Emax (maximal effect) of L-NMMA in type 1 diabetes patients and con-
trols. This approach will answer the question as to whether the NO pathway is
altered in non-complicated type 1 diabetes mellitus.
Methods
We recruited 8 non-complicated type 1 diabetes patients (DP) and 9 matched
healthy control subjects (C) from the local community. All subjects fulfilled the
following criteria: age between 18 and 40, blood pressure (BP) < 140/90 mmHg,
no antihypertensive medication and no signs of cardiovascular disease. Since
primary hypertension, atherosclerosis and smoking have been associated with an
impaired vasoconstrictor response to L-NMMA these subjects were excluded. All
subjects signed the informed consent and the study protocol was approved by the
local medical ethics committee.
Subjects were instructed to abstain from alcohol and caffeine for 24 h and
refrain from smoking 12 h before the study. The study was performed between
8.00-12.00 a.m. All subjects attended the clinic after an overnight fast. Fifteen
minutes after cannulation of the brachial artery of the non-dominant arm, intra-
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DM Subjects Controls p-value
(n=8) (n=9) between groups
Age (years) 29±3 22±1 NS
Gender (male:female) 5:3 4:5 NS
Body mass index (kg·m−2) 24.6±0.9 22.3±0.6 0.04
Duration of diabetes (months) 146±51 NA NA
HbA1c(%) 8.2±0.4 NA NA
Total daily insulin dose (units) 63±7 NA NA
Fasting glucose (mmol·L−1) 14.2±1.2 4.7±0.1 0.001
Baseline FBF (mL·min−1·dL−1) 2.6±0.2 2.1±0.2 NS
Values are expressed as means±SEM.
NA, not applicable; NS, not significant.
Table 8.1: Baseline characteristics of the participants in the study
arterial blood pressure was recorded for 5 minutes. Thereafter, forearm blood flow
(FBF) was measured by venous occlusion strain gauge plethysmography as de-
scribed before [166]. After assessment of the baseline FBF, increasing doses of the
NO-synthase inhibitor L-NMMA (0.01, 0.025, 0.05, 0.2, 0.4, 0.8 and 1.6mg·min−1
per dL forearm volume [mg·min−1·dL−1]) were infused into the brachial artery.
After each infusion period of five minutes for the respective doses, the effect of the
infusion of L-NMMA on FBF was measured by venous occlusion plethysmography
in the final two minutes.
Results are presented as means±SEM unless indicated otherwise. FBF is ex-
pressed in mL·min−1 per dL of forearm tissue (mL·min−1·dL−1). Delta FBF
(∆FBF) is calculated by subtracting the measured flow during infusion of study
medication from the FBF at baseline. Dose-response curves and pharmacody-
namic parameters (EC50 and Emax) were calculated individually, by means of
Graphpad Prism Sigmoid Emax-model. Student’s t-test was used to test for sig-
nificant differences in EC50 and Emax between both groups. Mann-Whitney-U
test was used to test for significant differences in non-parametric variables, oth-
erwise, Student’s t-test was used. Differences were considered to be significant at
p-values < 0.05.
Results
The baseline characteristics of both groups are shown in table 8.1. Besides fasting
plasma glucose and body mass index, DP and C did not differ significantly with
regard to any of the baseline characteristics. In DP as well as C FBF decreased
significantly during infusion of the increasing doses of L-NMMA. As shown in
table 8.1 DP and C did not differ significantly with regard to baseline FBF.
In both populations, the maximum decrease in FBF occurred during infusion
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of 0.8 mg·min−1·dL−1. The dose of 1.6 mg·min−1·dL−1 showed a significant
increase with respect to 0.8 mg·min−1·dL−1 in both groups (p<0.001). During
the experiment there were no significant differences between both groups with
regard to the response on L-NMMA infusion. As shown in figure 8.1C, there were
no significant differences between both groups regarding EC50 (DP: 0.017±0.001;
C: 0.022±0.001; NS) and Emax (DP: 1.13±0.1; C: 0.97±0.1; NS). All subjects
showed an increase in MAP (DP: 89±3 to 96±2 mmHg, p<0.005; C: 91±2 to
99±2 mmHg, p<0.001) during the experiment (figure 8.1D). Interestingly, FBF
remained constant in the control arm. The average MAP in C and DP was
not significantly different between both groups throughout the experiment. At
baseline there was no significant difference between FBF in the control forearm
and the FBF in the experimental arm neither DP nor in C. Neither did the FBF
in the control arm change significantly over time in both groups (figure 8.1A).
Discussion
This study is the first to compare the dose response of intra arterial infusion of
L-NMMA with complete maximal blockade on venous occlusion plethysmography
in type 1 diabetes patients and healthy controls. Pharmacodynamic parameters
(EC50, Emax) were identical in both groups. Although there is abundant litera-
ture about altered NO metabolism in (early) type 1 diabetes [184; 186–190], we
were unable to find a difference in pharmacodynamics in L-NMMA between non-
complicated DP and healthy controls. Several explanations can apply for this
observation. First, we studied a non-complicated diabetes population. Appar-
ently endothelial dysfunction is not present at this early state of diabetes. Even,
baseline forearm blood flow was borderline significantly higher in the diabetes pa-
tients. Some studies indicate that early type 1 diabetes mellitus is characterized
by relative hyperemia [65; 187]. Second, perhaps early type 1 diabetes mellitus is
not characterized by altered NO metabolism, but alterations in other regulators
of vascular tone like decreased noradrenergic vasoconstrictive tone or increased
vasodilator prostanoids [185]. Vervoort et al. [65] showed that early type 1 dia-
betes mellitus is characterized by decreased vasoconstrictive noradrenergic tone,
resulting in hyperemia. They could not find any difference in the NO pathway or
endothelial dependent vasodilation induced by acetylcholine.
In both populations the maximal inhibiting dose (0.8 mg·min−1·dL−1) is
higher than used in most venous occlusion plethysmography studies [181; 185;
191–198]. Most venous occlusion plethysmography studies used doses of 0.2-0.4
mg L-NMMA ·min−1·dL−1. This indicates that the NO-synthase inhibition in
these studies has been sub-optimal. As it is not clear whether differences in phar-
macodynamics exists between various study populations, suboptimal blockade of
NO synthesis will result in spurious conclusions. Therefore, results from those
studies have to be taken with caution. In our study we used increasing doses of
L-NMMA to determine the concentration at which maximal blockade of nitric ox-
ide synthase occurs. Cohen et al. [199] have clearly shown that in isolated artery
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Figure 8.1: (A) Absolute forearm blood flow in the control arm of type 1 diabetes
patients () and healthy controls (©) in response to increasing doses of L-NMMA. (B)
Absolute forearm blood flow in the experimental arm of type 1 diabetes patients () and
healthy controls (©) in response to increasing doses of L-NMMA. (C) Absolute change
in forearm blood flow in the experimental arm of type 1 diabetes patients () and healthy
controls (©) in response to increasing doses of L-NMMA. (D) change in mean arterial
pressure in type 1 diabetes patients () and healthy controls (©) in response to increasing
doses of L-NMMA.
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segments NO production is not completely abolished despite maximal blockade of
nitric oxide synthase. During maximal blockade of nitric oxide synthase with two
L-arginine analogs they still could determine the increase in nitric oxide produc-
tion in response to acetylcholine exposure. Therefore, although maximal blockade
of NOS was achieved in our study, residual nitric oxide synthase activity may be
present and blockade may not have been complete. Interestingly the highest dose
of L-NMMA (1.6 mg·min−1·dL−1) showed a smaller decrease in FBF compared
to 0.8 mg·min−1·dL−1. Probably this can be attributed to a systemic effect of
L-NMMA. As indicated in figure 8.1C a dose of 0.025 mg·min−1·dL−1 already
induced 50% of the vasoconstrictor effect. This proves the sensitivity of the vas-
cular endothelium for L-NMMA. The MAP showed a progressive equal increase in
both study groups. This points towards systemic vasoconstriction. At the highest
dose of L-NMMA, the FBF appeared to be higher than during previous dosages.
This is probably the result of the increase in MAP during the highest dose.
In conclusion, non-complicated type 1 diabetes patients and control subjects
show identical pharmacodynamics on infusion of L-NMMA. This suggests that at
this early stage of type 1 diabetes no differences in the NO pathway exists. The
maximal inhibiting concentration of L-NMMA is 0.8 mg·min−1·dL−1. This is
higher than most commonly used L-NMMA doses. At high dosages of L-NMMA
a systemic effect cannot be ruled out.
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nephropathy in a prospective study
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Abstract
Background Renal complications determine to a great extent the morbidity and
mortality in type 1 diabetes mellitus. Historical registries indicated that up to
40% of type 1 diabetes patients developed diabetic nephropathy. To investigate
prognostic factors for the development of diabetic nephropathy in type 1 diabetes
mellitus, a large prospective study (PROFID-study) was initiated in 1994. One
hundred forty-eight normotensive type 1 diabetes patients without nephropathy
were included in the study. At inclusion they were not treated with antihyper-
tensive medication, had a diabetes duration of 5 to 12 years and their age was
between 18 and 40 years. At the start of the study we anticipated an event rate
(development of micro-albuminuria) of 20% after 12 years of follow-up. After 12
years of follow-up the cumulative incidence of diabetic nephropathy is 6%, far
lower than expected. To elucidate whether this lower incidence of diabetic ne-
phropathy reflects a change in the natural history of type 1 diabetes or whether
the study suffered from selection bias or poor follow-up, we compared the study
population with type 1 diabetes patients, who were treated in our hospital during
the study period, who fulfilled the inclusion criteria but who refused to participate
in the study.
Methods From current and historical local registries 769 type 1 diabetes patients
were identified. Sixty-three patients participated in the PROFID-study. One
hundred sixty-four patients fulfilled the inclusion criteria for the PROFID-study
but did not participate. Both groups were compared with regard to the inci-
dence of diabetic nephropathy, glycemic control, blood pressure regulation and
demographic characteristics.
Results Both groups did not differ with regard to the cumulative incidence of
diabetic nephropathy, glycemic control, blood pressure regulation, use of antihy-
pertensive medication or demographic characteristics.
Conclusions The observed reduced incidence of diabetic nephropathy among par-
ticipants of the PROFID study is not caused by selection bias. This suggests a
change in the disease course of type 1 diabtes mellitus.
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Introduction
Renal complications determine to a great extent the morbidity and mortality in
type 1 diabetes mellitus. Historical registries indicated that up to 40% of type
1 diabetes patients developed diabetic nephropathy [10; 15; 200]. To investigate
prognostic factors for the development of diabetic nephropathy in type 1 diabetes
mellitus, a large prospective study was initiated in 1994 (PROgnostic Factors In
Diabetic nephropathy, the PROFID-study). The PROFID-study recruited 148
normotensive type 1 diabetes patients without nephropathy. After 12 years of
follow up the cumulative incidence of diabetic nephropathy amounted 6%, lower
than expected. To elucidate whether this lower incidence of diabetic nephropathy
reflects a change in the disease course of type 1 diabetes or is merely explained by
selection bias, we compared the study population with eligible, non-participating
type 1 diabetes patients.
Methods
In the PROFID-study, 148 type 1 diabetes patients were included. At inclusion
they were normoalbuminuric, not treated with antihypertensive medication, had
a diabetes duration of 5 to 12 years and their age was between 18 and 40 years.
Patients were recruited from the out-patient clinic of the Radboud University
Medical Centre, but also from affiliated hospitals. Of the 148 PROFID-study
participants, 63 were treated in our out-patient clinic. At baseline extensive
studies were performed in the participants as described in Chapter 1 (Introduction
and Outline). Follow-up consisted of biannual measurement of urinary albumin
excretion rate (UAE) and regular blood pressure measurements.
From local historical and current registries of type 1 diabetes mellitus patients,
769 type 1 diabetes patients were identified who visited our out-patient clinic in
the study period. Of these, 164 patients fulfilled the inclusion criteria, but did
not participate. Of both groups, charts were reviewed and from onset of diabetes
all office blood pressure measurements, all (changes in) antihypertensive medi-
cation were registered. HbA1c levels and presence of (micro) albuminuria were
documented. We investigated whether there were differences in demographic char-
acteristics, glycemic control, blood pressure regulation and incidence of diabetic
nephropathy.
Definition of nephropathy All patients were tested for albuminuria at regular in-
tervals. Urinary albumin was measured in a timed overnight urine sample using
immunonephelometry. Nephropathy was diagnosed if microalbuminuria (> 20
µg·min−1) was detected in two or more consecutive urine samples.
Measurement of glycosylated haemoglobin Measurement of glycosylated haemoglo-
bin became routine in 1980. HbA1 was measured using a chromatographic method,
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participants non-participants
(n=63) (n=164)
Age of onset 19±8 20±8
of diabetes (years±SD)
Male 29 (46%) 91 (55%)
Average duration of diabetes 18.4±3 17.4±3
until 2007 (years±SD)
(Ever) smokers (%) 25 (47%) 56 (40%)∗
Antihypertensive treatment (%) 8 (13%) 18 (11%)
Diabetic nephropathy (%) 4 (6%) 7 (4%)
Mortality (%) 2 (3%) 5 (3%)
∗ Information on smoking habits was available for 139 subjects .
Table 9.1: Characteristics of participants of the PROFID-study compared with eligible,
non-participating type 1 diabetes patients
with a reference value of 5.5-8.5% [201]. In 1989 the method for analyzing gly-
cosylated haemoglobin changed from HbA1 determination to HbA1c. HbA1c was
measured using a HPLC technique (Bio-Rad Diamat, the Netherlands), with ref-
erence values of 4.8-6.2%. We have evaluated the relationship between HbA1 and
HbA1c. The following relationship was observed: HbA1c = 0.6476[HbA1]+1.869.
For the present study all HbA1 values were replaced by calculated HbA1c values.
Statistical analysis Differences between groups with regard to mortality, sex, smok-
ing habits, antihypertensive treatment and the development of diabetic nephro-
pathy were compared by χ2 test. Differences between groups with regard to age
of onset and the duration of diabetes were tested using Student’s t-test. A p-value
less than 0.05 was considered statistically significant.
Results
Of 769 type 1 diabetes patients 227 were eligible for participation in the PROFID-
study. Sixty-three patients from the Radboud University Medical Centre partic-
ipated in this study whereas 164 did not participate. Table 9.1 shows the char-
acteristics of the non-participating subjects and the participants. There were no
differences in age at onset of diabetes, gender, duration of diabetes at end of
follow-up, and the percentage of smokers. During follow-up 8 participants (13%)
were treated with antihypertensive medication, compared to 18 non-participants
(11%; p= NS). As shown in figure 9.1 there were no differences with regard to
blood pressure regulation (upper panel) as well as glycemic control (lower panel).
Two (3%) participants of the PROFID study died, versus five (3%) of the non-
participating subjects (p= NS). At the end of follow-up four participants (6%)
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patients had developed diabetic nephropathy, and seven non-participants (4%;
p= NS).
Discussion and conclusion
The observed incidence of diabetic nephropathy in the PROFID-study popula-
tion is far lower than reported in historical registries. However, the observed
incidence in the study population is equal to the incidence of diabetic nephropa-
thy in eligible, non-participating subjects followed during the same time period.
There were no differences between participants and non-participants with regard
to glycemic control, blood pressure, treatment with antihypertensive medication,
smoking habits and sex. Therefore, the lower than expected incidence of diabetic
nephropathy in the PROFID-study is not caused by selection bias, but most likely
reflects a change in the disease course of type 1 diabetes mellitus.
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Figure 9.1: The upper panel shows the average systolic and diastolic blood pressure
(mmHg±SD) for participants of the PROFID-study (closed boxes and circles) and non-
participating, but eligible type 1 diabetes patients (open boxes and circles). The lower
panel shows the average HbA1(c) levels (%±SD) for participants of the PROFID-study
(closed boxes) and non-participating, but eligible type 1 diabetes patients (open circles).
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Abstract
Background The development of renal complications is a major determinant of
the increased morbidity and mortality in patients with type 1 diabetes mellitus.
The cumulative incidence of diabetic nephropathy was 20-40%. However, recent
studies suggest that the incidence may be decreasing. Both improved glycemic
control and improved blood pressure regulation may be responsible.
Methods We assessed trends in the cumulative incidence of diabetic nephropathy
in a retrospective population study and evaluated treatment practice with regard
to blood pressure and glycemic control. Seven hundred sixty-nine patients were
identified, who visited the out-patient clinic of the Radboud University Nijmegen
Medical Centre and were followed from onset of diabetes to 2007 or to death. Pa-
tients with persistent albuminuria were considered to have diabetic nephropathy.
From 1980 onwards glycosylated haemoglobin was measured regularly.
Results The cumulative incidence of diabetic nephropathy after 20 years of diabe-
tes decreased from 17.3% among patients who developed type 1 diabetes between
1970 and 1974 to 7.7% in patients who developed diabetes between 1985 and 1989.
Overall, we observed an improved glycaemic control over time, average HbA1c de-
creasing from 9.5% in 1980 to 8.0% in 2006. Although the percentage of patients
treated with antihypertensive drugs increased from 9 to 25% no major change in
average blood pressure was observed. In a Cox’s proportional hazard regression
model, year of diagnosis, time-averaged HbA1c and time-averaged diastolic blood
pressure were independent predictors of the development of diabetic nephropathy.
In a case control analysis, patients who developed diabetic nephropathy (cases)
were more likely to have higher levels of glycosylated haemoglobin compared to
patients who remained normoalbuminuric (controls). Prior to the development
of diabetic nephropathy, cases also had higher blood pressure values, even de-
spite being treated more often with antihypertensive medication. There was no
significant difference in smoking habits between both groups.
Conclusions In type 1 diabetes mellitus the cumulative incidence of diabetic ne-
phropathy has decreased dramatically over the past decades. This improvement
concurred with substantially improved glycemic control and intensified treatment
with antihypertensive medication. Both the population study and the case-control
study show that glycemic control as well as elevated blood pressure values are de-
terminants for the development of diabetic nephropathy. As throughout the years
glycemic control improved substantially while blood pressure levels remain virtu-
ally unchanged, apparently there is opportunity for intensifying antihypertensive
treatment. Perhaps this may lead to a further reduction of the incidence of dia-
betic nephropathy.
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Introduction
Renal complications are a major determinant of morbidity and mortality in pa-
tients with type 1 diabetes mellitus. Previous studies reported a cumulative inci-
dence of 20-40% of diabetic nephropathy [10; 15; 200].
Various modifiable risk factors may contribute to the development of diabetic
nephropathy. The DCCT trial [35; 202] and the ADVANCE-study [203] clearly
showed that improved glycemic control lowered the cumulative incidence of dia-
betic nephropathy. Also tight blood pressure regulation reduces the incidence and
the progression of diabetic nephropathy [1; 58; 60]. Smoking increases the risk
of diabetic nephropathy[204]. In recent years some [12; 205] but not all studies
[200; 206] reported a decreased incidence of diabetic nephropathy.
In 1994 we initiated a prospective study to elucidate prognostic factors for the
development of diabetic nephropathy in patients with type 1 diabetes mellitus
[65; 96]. One hundred and fourty-eight type 1 diabetes patients were included.
All patients were normoalbuminuric, normotensive and had a diabetes duration of
5-12 years. Thus far only 6 patients (4%) developed microalbuminuria after 8-14
years of follow-up, suggesting that the natural history of diabetic nephropathy
is changing. Therefore, we investigated, in a historical cohort, trends in the
cumulative incidence of diabetic nephropathy. Also we evaluated the possible role
of blood pressure regulation and glycemic control.
Methods
From local historical and current registries of type 1 diabetes patients 944 type
1 diabetes patients were identified. Of those 944 patients, 769 patients were nor-
moalbuminuric and did not receive antihypertensive medication at the beginning
of follow up. The charts of those 769 patients were reviewed. All office blood pres-
sure recordings and all (changes in) antihypertensive medication were registered.
Smoking habits, HbA1c levels and presence of (micro) albuminuria were docu-
mented. For the analysis of the change in the cumulative incidence of diabetic
nephropathy, the patients were divided into 5-yr cohorts, according to the year
in which diabetes was diagnosed (1970-1974, 1975-1979, 1980-1984, 1985-1989,
1990-1994, 1995-1999, 2000-2005).
Definition of nephropathy All patients were tested for proteinuria at regular in-
tervals, initially with a semi-quantitative test strip (Albustix®), since 1985 by
measuring albumin in a timed overnight urine sample using immunonephelom-
etry. Nephropathy was diagnosed if albuminuria was detected in two or more
consecutive urine samples.
Measurement of glycosylated haemoglobin Measurement of glycosylated haemoglo-
bin became routine in 1980. HbA1 was measured using a chromatographic method,
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with a reference value of 5.5-8.5% [201]. In 1989 the method for analyzing glycosy-
lated haemoglobin changed from HbA1 determination to HbA1c. HbA1c was mea-
sured using a HPLC technique (Bio-Rad Diamat®, the Netherlands), with refer-
ence values of 4.8-6.2%. We evaluated the relationship between HbA1 and HbA1c.
The following relationship was calculated: HbA1c = 0.6476·[HbA1]+1.869. For
the present study all HbA1 values were replaced by calculated HbA1c values.
Case-control analysis Within the cohort, for every patient that developed diabetic
nephropathy (case) one matched patient without diabetic nephropathy (control)
was selected. Eight patients with diabetic nephropathy could not be matched due
to their high age. One hundred and seven cases and controls were matched for
sex, age, age of onset of diabetes, and duration of follow-up. We compared cases
and controls with regard to blood pressure regulation, glycemic control, smoking
habits, blood pressure before onset of diabetic nephropathy and blood pressure
before treatment of hypertension. In controls, blood pressure (treatment) and
glycemic control were analyzed with regard to the date of onset of diabetic ne-
phropathy in their matched case. Of both cases and controls the average HbA1c,
systolic blood pressure and diastolic blood pressure, prior to the development
of diabetic nephropathy, were estimated by calculating the area under the curve
(AUC) for all three variables. For an individual, the AUC was calculated by mul-
tiplying the average of two consecutive values by the time interval (months) for all
recordings until an end point was reached (development of diabetic nephropathy,
death or end of study). The sum of those calculations was divided by the total
number of months prior to the development of the end points.
Statistics Differences between groups were calculated with Student’s t-test or
Mann-Whitney-U -test when appropriate. Differences in frequencies (like smok-
ing habits) between groups were compared by the χ2-square-test. Univariable
analysis was used to identify possible explanatory variables for the development
of diabetic nephropathy. To test the relative contributions of selected variables
on the development of diabetic nephropathy, a Coxs proportional hazard regres-
sion model was used. To test the relative contributions of selected variables on
the development of diabetic nephropathy, a stepwise multiple regression analysis
was performed with AUC HbA1c, AUC systolic blood pressure, AUC diastolic
blood pressure, ever-smoking status and use of antihypertensive medication prior
to the development of diabetic nephropathy as independent variables and the
development of diabetic nephropathy as the dependent variable.
A p-value < 0.05 was considered statistically significant. All calculations
were performed with SPSS 15.0 (SPSS, Chicago, USA) or Graphpad PRISM 5.01
(Graphpad software, La Jolla, USA)
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n = 769
Male gender (%) 49
(Ever) smokers (%) 49
Age of onset (years±SD) 20±12
Follow-up (years±SD) 15.8±9
Diabetic nephropathy (%) 13.9
Use of antihypertensive medication (%) 33
Mortality (%) 6
Table 10.1: Characteristics of all type 1 diabetes patients
Figure 10.1: Average HbA1c (%) values in type 1 diabetes mellitus patients over the
years.
Results
From local historical and current registries of patients with type 1 diabetes 944
patients were identified. Of those, 769 were normoalbuminuric and did not receive
antihypertensive medication at the beginning of follow up. The characteristics of
this study cohort are described in table 10.1.
Figure 10.1 shows the average HbA1c levels from 1980 up to 2006. There was a
sharp decline in HbA1c levels shortly after the introduction of HbA1c measurement
in 1980. Thereafter, a gradual decrease of HbA1c occurred. The mean HbA1c level
was 8.6±1.4% in the period 1985–1995 and 8.3±1.5% in the period 1996-2006.
In figure 10.2, the average systolic and diastolic blood pressures are depicted
for all patients studied in the period from 1980 up to 2006. Office blood pressures
i
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Figure 10.2: The average office systolic and diastolic blood pressure values
(mmHg±SD) in patients with type 1 diabetes mellitus over the years.
did not change significantly during this observation period.
The cumulative incidence of patients who received antihypertensive treatment
is depicted in figure 10.3. Only 9% of patients who developed diabetes mellitus
between 1970 and 1974 received antihypertensive drugs at 20 years after onset,
compared to 25% of patients who developed diabetes mellitus between 1985 and
1989. Twenty-seven patients without nephropathy and 21 patients with nephro-
pathy died.
During the study period, 115 patients developed diabetic nephropathy. A
Coxs proportional hazard model was used to develop a model for predicting the
development of diabetic nephropathy, using year of diagnosis, AUC HbA1c, AUC
systolic blood pressure, AUC diastolic blood pressure, ever-smoking status and
sex as independent variables and the development of diabetic nephropathy as the
dependent variable. Year of diagnosis, AUC HbA1c and AUC diastolic blood
pressure had a significant partial effect in the full model (table 10.2).
The cumulative incidence of nephropathy for the successive 5-yr cohorts is
shown in figure 10.4. With increasing year of diagnosis the cumulative incidence
of nephropathy decreased: after 20 years of diabetes, the cumulative incidence
of diabetic nephropathy decreased from 17.3% for patients who developed type
1 diabetes between 1970 and 1974 to 7.7% for patients who developed diabetes
between 1985 and 1989.
Onset of diabetic nephropathy for tertiles of HbA1c levels or blood pressure
levels is illustrated in figures 10.5 and 10.6. Of note, figure 10.5 indicates that
i
i
“thesis” — 2009/9/17 — 20:34 — page 83 — #89 i
i
i
i
i
i
Declining incidence of diabetic nephropathy 83
Figure 10.3: The cumulative incidence (%) of antihypertensive treatment according to
the year of onset of type 1 diabetes mellitus.
Cox’s-regression model
population study
Variable Beta (p-value)
Year of diagnosis -0.05 (p<0.05)
AUC HbA1c∗ 0.80 (p<0.001)
AUC SBP∗ NS
AUC DBP∗ 0.05 (p<0.05)
Ever smoking NS
Gender NS
∗ Prior to the development of diabetic nephropathy.
AUC, area under the curve; SBP, systolic blood pressure;
DBP, diastolic blood pressure; HbA1c, glycosilated haemoglobin A1c;
NS, not significant
Table 10.2: Effects of selected variables on the probability of development of diabetic
nephropathy.
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Figure 10.4: The cumulative incidence (%) of diabetic nephropathy according to the
year of onset of type 1 diabetes mellitus.
Figure 10.5: Cumulative incidence of diabetic nephropathy according to AUC HbA1c
levels prior to the development of diabetic nephropathy. Population divided into tertiles
according to HbA1c.
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Figure 10.6: Cumulative incidence of diabetic nephropathy according to AUC diastolic
blood pressure prior to the development of diabetic nephropathy. Population divided into
tertiles according to AUC diastolic blood pressure.
the relation between HbA1c level and risk of diabetic nephropathy is not linear;
we observed no difference in the incidence of diabetic nephropathy between pa-
tients with HbA1c levels < 7.8% and 7.8-8.6%. However, the incidence was clearly
increased in patients with HbA1c levels > 8.6%. Figure 10.6 shows that with in-
creasing diastolic blood pressure the risk for development of diabetic nephropathy
increases.
Development of diabetes mellitus during childhood (age < 16 years) was asso-
ciated with an increased risk for the development of diabetic nephropathy (figure
10.7). However, patients who developed diabetes mellitus before the age of 16
years had a higher AUC HbA1c compared with patients who developed diabetes
mellitus at an age above 15 years (8.4±1.2% vs 8.1±1.1%, p<0.02). Thus, when
age of onset of diabetes was entered into the COX-regression analysis, it was not
a significant independent risk factor for the development of diabetic nephropathy.
Case-control analysis
Glycemic control In the case-control analysis, patients who developed nephro-
pathy had a higher HbA1c in the period from onset of diabetes to development of
nephropathy as compared with patients who remained normoalbuminuric (figure
10.8 panel B). Even after the development of nephropathy, HbA1c remained higher
than the HbA1c levels of patients who remained normoalbuminuric (not shown).
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Figure 10.7: Cumulative incidence of diabetic nephropathy (%) in patients with onset
of diabetes before the age of 16 and from the age of 16 onwards.
The average HbA1c (AUC) before the development of diabetic nephropathy in
cases was 9.5±1.4% while in controls it was 8.4±0.9% (p<0.001).
Blood pressure regulation Panel A of figure 10.8 shows the average systolic and
diastolic blood pressure prior to the development of diabetic nephropathy over the
years. During the months prior to the initiation of antihypertensive medication,
blood pressure was higher in cases as compared with controls (systolic blood pres-
sure: 143±2 mmHg vs 133±2 mmHg; p=0.002; diastolic blood pressure: 83±1
mmHg vs 75±1 mmHg; p<0.001). When comparing blood pressure between cases
and controls in the months prior to the development of nephropathy, blood pres-
sure was higher in cases as compared with controls (systolic blood pressure 138±2
mmHg vs 130± 2 mmHg; p=0.002; diastolic blood pressure 80±1 mmHg vs 74±1
mmHg; p=0.001). Cases were more likely to be treated with antihypertensive
medication prior to the development of diabetic nephropathy than controls did
(cases: 55 / 107 vs controls: 20 / 107; p<0.001). For cases, the average systolic
blood pressure (AUC) in the period from onset of diabetes until the develop-
ment of diabetic nephropathy was 135±15 mmHg while in controls it was 132±13
mmHg (p=NS). For the average diastolic blood pressure (AUC) it was 79±9
mmHg and 76±6 mmHg respectively (p<0.01). In cases and controls receiving
antihypertensive medication, blood pressure initially decreased from 147±18 to
143±21 after the initiation of antihypertensive medication (p<0.05). After two
years of treatment with antihypertensive medication blood pressure levels were
not significantly different from the pre-treatment values. In our study population,
the first ACE-inhibitors were introduced in 1984. Treatment with ACE-inhibitors
became widespread in the early nineties.
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Figure 10.8: Case-control study. Panel A shows the average blood pressure (mmHg ±
SD) of cases, prior to the development of diabetic nephropathy, and the average blood
pressure of the control subjects. Panel B shows the average HbA1c level (%±SD) of
cases, prior to the development of diabetic nephropathy, and the HbA1c level of the
control subjects.
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Stepwise multiple regression model
Case-control study
Variable Beta (p-value)
AUC HbA1c∗ 0.48 (p<0.001)
AUC SBP∗ NS
AUC DBP∗ NS
Ever smoking NS
Antihypertensive usage 0.21 (p<0.01)
∗ Prior to the development of diabetic nephropathy.
AUC, area under the curve; SBP, systolic blood pressure;
DBP, diastolic blood pressure; HbA1c, glycosilated haemoglobin A1c;
NS, not significant
Table 10.3: Effects of selected variables on the probability of development of diabetic
nephropathy.
Among cases 61 (57%) patients were (ever) smokers while 52 (54%) controls
(ever) smoked (p=NS).
A stepwise multiple regression analysis was used to develop a model for pre-
dicting the development of diabetic nephropathy, from AUC HbA1c, AUC systolic
blood pressure, AUC diastolic blood pressure, ever-smoking status and the use
of antihypertensive medication prior to the development of diabetic nephropathy.
The AUC HbA1c and use of antihypertensive medication prior to the develop-
ment of diabetic nephropathy had a significant partial effect in the full model
(table 10.3). The model was able to predict 24% of the development of diabetic
nephropathy (r2=0.24). AUC systolic or diastolic blood pressure did not predict
the development of diabetic nephropathy.
Discussion
Our data clearly demonstrate that the natural history of type 1 diabetes mellitus
is changing in our region. We observed a 10% decrease in the cumulative inci-
dence of diabetic nephropathy when comparing patients with onset of diabetes
in the period 1970-1974 and patients with onset of diabetes in the period 1985-
1989. Our data suggest that the decreasing incidence of diabetic nephropathy in
recent decades is caused by improvement of glucose control and earlier start of
antihypertensive therapy.
To analyze risk factors for the development of diabetic nephropathy, we eval-
uated the data for the cohort of patients with type 1 diabetes mellitus. Cox’s
proportional hazard analysis revealed year of diagnosis, average HbA1c and aver-
age diastolic blood pressure as independent risk factors for diabetic nephropathy.
The case control study strengthened these findings. Cases had higher HbA1c lev-
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els, were treated more frequently with antihypertensive medication, had higher
blood pressures before the onset of diabetic nephropathy and had a higher cumu-
lative diastolic blood pressure burden (AUC diastolic blood pressure).
Poor glycemic control has been identified as a risk factor for the development
of diabetic nephropathy in many observational [12; 206–209] as well as prospective
studies [35; 203]. Interestingly, when dividing our study population into tertiles
according to AUC HbA1c, there appears to be a threshold above which the risk
of development of diabetic nephropathy increases dramatically (HbA1c > 8.6%).
The risk for development of diabetic nephropathy appears not to be linear: further
reductions of HbA1c below the level of 8.6% does not seem to result in a lower risk
for the development of diabetic nephropathy. This is in accordance with other
studies. In the United Kingdom Prospective Diabetes Study [210] reduction of
HbA1c from 8 to 7% did not result in a reduced cardiovascular risk, although a
metformin-treated subgroup had a lower risk of cardiovascular events. Also, the
recent Action to Control Cardiovascular Risk in Diabetes (ACCORD)-trial [211]
did not show a reduced cardiovascular risk when using intensive therapy to target
normal HbA1c (< 6.0 vs 7.5%) levels for 3.5 years. In this study, a change in devel-
opment of diabetic nephropathy was not reported. In their study of nephropathy
in childhood type 1 diabetes Amin et al. [212] showed a high cumulative incidence
of diabetic nephropathy. The high incidence can be explained since three quarter
of their patients had an average HbA1c level above 8.5%. With HbA1c < 8.5%
as the lowest quartile, the risk of development of diabetic nephropathy increased
progressively with increasing quarters of HbA1c. However, even when HbA1c-
levels are below 8.5%, diferences in HbA1c-levels might be relevant. A study in
type 2 diabetes patients [203] showed a significant reduction in the development
of nephropathy with intensive glucose control as compared with regular glucose
control (HbA1c 6.5 vs 7.5%).
In our study HbA1c levels improved dramatically over time, especially shortly
after the introduction of HbA1c. This sudden and remarkable decrease of HbA1c
levels is notable. It is not clear what caused this decrease in HbA1c. In 1980
the HbA1c determination was introduced in our hospital. Within two years after
introduction, HbA1c levels decreased. Perhaps the introduction of HbA1c itself
made patients and their doctors aware of the actual level of glycemic control and
stimulated their efforts for stricter glycemic control. An other explanation may
be the introduction of self-monitoring of blood glucose. Initially, self-monitoring
consisted of urine glucose measurements three times a day. In the early eighties
self-monitoring of blood glucose became standard. Frequent self-monitoring of
blood glucose improves glycemic control [213]. Also treatment regimens changed
dramatically: while patients were treated initially with a single morning dose
of long acting insulin, nowadays many patients are on treatment with multiple
daily injections or even insulin pumps for continuous administration of insulin.
Besides, education of patients improved, and the treatment was more adjusted to
the patients life style.
In contrast to the improvement of HbA1c, average blood pressure did not
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change during the study period, although patients in the most recent years were
treated more often with antihypertensive agents. Thus, it is unlikely that improve-
ment in blood pressure control contributed to the decreased incidence of diabetic
nephropathy. Admittedly one might suggest that antihypertensive treatment per
se, independent of blood pressure levels could protect against the development of
diabetic nephropathy. However, the case-control study argues against this con-
clusion: in the case-control study antihypertensive treatment rather than blood
pressure level per se, was an independent risk factor for development of diabetic
nephropathy, suggesting that a treated blood pressure level is not comparable to
the same blood pressure level untreated. Obviously, data from a retrospective
study cannot be used to determine the contributory role of various risk factors
in the decreased incidence of diabetic nephropathy. Meanwhile, large prospective
studies have clearly shown that intensified glucose control and strict antihyper-
tensive therapy improved renal outcome in type 1 diabetes mellitus patients.
Some studies [12; 205; 214] but not all [200; 206; 208] have reported a declin-
ing incidence of diabetic nephropathy. A study of Bojestig et al. [12], showed
a decline in incidence of diabetic nephropathy. This decline was associated with
improved glycemic control, and not related to antihypertensive treatment, since
only a very small number of patients without diabetic nephropathy were receiving
such therapy. In a study by Hovind et al. [205], the decrease in the incidence
of diabetic microangiopathy with increasing calendar year of diagnosis, was as-
sociated with improved glycemic control, earlier initiation of antihypertensive
medication and lower blood pressure levels. Nordwall et al. [214] also reported
a decrease in incidence of diabetic nephropathy. Although blood pressure values
were not investigated, they suggest that the decreased incidence of diabetic ne-
phropathy did not result from improved blood pressure regulation, as the decrease
occurred before the wide spread use of ACE inhibitors and other antihyperten-
sive medication. Other studies failed to show a decrease in incidence of diabetic
nephropathy. Tryggvason et al. [208] failed to show a decline in the incidence
of diabetic nephropathy in their nationwide study in Iceland. In this study, the
development of diabetic nephropathy was associated with poor glycemic control.
Rossing et al. [200] also failed to show a change in incidence of diabetic nephro-
pathy. In their study the development of microalbuminuria was associated with
poor glycemic control. No relationship with blood pressure or antihypertensive
use was reported. Pambianco et al. [206] also failed to demonstrate a decline in
diabetic nephropathy, although in their study, the incidence of end stage renal
failure was declining among type 1 diabetes patients. Glycemic control and blood
pressure regulation were not investigated.
Admittedly, our study has several limitations. We tried to select all current
and historic type 1 diabetes patients controlled at the outpatient clinic of the
Radboud University Nijmegen Medical Centre. As we selected our patients ret-
rospectively there is a change that patients died prematurely, with the risk of
selection bias. The patients with early diabetic nephropathy or those most at risk
for developing diabetic nephropathy may have died prematurely, influencing the
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results. If this bias is applicable, it would underestimate the improvement in the
change in natural history of diabetic nephropathy, as it is likely that most selec-
tion bias occurred in the eldest cohorts. To correct for a possible effect of selection
bias we analyzed the cohort in a case-control manner. In our case-control analysis,
eleven control subjects died during follow-up after their reciprocal case developed
diabetic nephropathy. These patients could have developed diabetic nephropathy.
This can have weakened the results of this analysis. We defined nephropathy as
two or more consecutive positive tests for urinary albumin (albustix® positive or
timed urine collection). As the former is less sensitive than the latter, this tends to
underestimate the cumulative proportion of diabetic nephropathy in the older co-
horts compared with the younger cohorts. Despite this possible underestimation,
the older cohorts showed a increased incidence of diabetic nephropathy.
Conclusions
Our study demonstrates a decrease in the cumulative incidence of diabetic nephro-
pathy in type 1 diabetes mellitus over the past decades. This improved outcome
is largely explained by the parallel improvement in glucose control. Our analysis
revealed that blood pressure was also a risk factor for the development of dia-
betic nephropathy. Since average blood pressure levels did not decrease over the
past decades, there may be opportunities to further reduce the risk of diabetic
nephropathy by more aggressive lowering of blood pressure.
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Summary of the thesis
The presence of micro- and macrovascular complications determines to a great
extent the prognosis of patients with type 1 diabetes mellitus. Besides being a
prognostic factor for the development of end stage renal disease, the presence of
diabetic nephropathy is also associated with an increased risk for the development
of cardiovascular disease. Microalbuminuria, the presence of slightly elevated
amounts of albumin in the urine, is currently the strongest predictor for the
development of diabetic nephropathy.
To better understand the factors underlying the development of diabetic ne-
phropathy, we have initiated a prospective study in 1994. One-hundred-and-forty-
eight patients with type 1 diabetes mellitus, with a duration of diabetes of 5 to 12
years at inclusion, without micro- or macrovascular disease, were followed upto
13 years for the development of diabetic nephropathy. At entry, these patients
underwent an extensive study protocol. This protocol was designed to investigate
mechanisms possibly involved in the development of diabetic nephropathy.
The rationale for the study is described in chapter 1.
While awaiting the results of the prospective study, several descriptive and
physiological studies were performed which are described in this thesis. In this
summary, the results of these studies and their clinical implications will be dis-
cussed and put into perspective.
Descriptive and physiological studies
Chapter 2 describes an overview of the literature (2002) with regard to factors
which are held responsible for the development of diabetic nephropathy.
Several hypotheses exist about the pathophysiology of diabetic nephropathy.
Metabolic and haemodynamic changes both seem to play important roles in the
development of diabetic nephropathy. Hyperglycemia seems crucial for the induc-
tion of metabolic changes, like, among others, the formation of advanced glycation
end products, and the activation of protein kinase C and transforming growth
factor-β. Others put forward the haemodynamic hypothesis, in which haemody-
namic alterations provoke structural changes. Thusfar no single mechanism has
been presented which can be held responsible for the development of diabetic
nephropathy.
Increased glomerular filtration Early in the course of diabetes, the kidneys hyper-
trophy, and glomerular filtration is increased. This increased glomerular filtration
is (partly) held responsible for the development of diabetic nephropathy, as it can
lead to increased glomerular pressure. These haemodynamic changes may cause
injury to the capillary wall, resulting in increased permeability, mesangial sclerosis
and glomerular basement membrane thickening.
The cause of the glomerular hyperfiltration is unknown. Glomerular hyperfil-
tration is attributed to vasodilation predominatly at the afferent arteriole. Many
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humoral factors have been implicated in glomerular hyperfiltration. Recently, it
has been proposed that the glomerular hyperfiltration finds its origin not pri-
marily in the glomerulus, but in a primary increase in proximal tubular sodium
reabsorption. This than leads to a systemic volume expansion. We investigated
whether the primary event leading to systemic volume expansion is caused by a
glomerular or a tubular event. Chapter 3 describes that increased proximal tubu-
lar sodium reabsorption contributes to the increased glomerular hyperfiltration.
This study does not support the hypothesis that the increase in glomerular filtra-
tion results from systemic volume expansion or an increase in atrial natriuretic
peptide.
Homocysteine Homocysteine has long been seen as a (causal) factor for atheroscle-
rosis and as an independent risk factor for cardio-vascular disease. Despite the
fact that type 1 diabetes mellitus is often complicated by vascular disease, plasma
homocysteine levels are reduced in type 1 diabetes mellitus. Plasma homocysteine
levels appear to be determined by glomerular filtration. As (early) type 1 dia-
betes mellitus is characterized by increased glomerular filtration, we investigated
whether the increased glomerular filtration could contribute to reduced plasma
homocysteine levels. Chapter 4 describes the results of an analysis in our cohort
with regard to the influence of renal function on plasma homocysteine levels. In
our study cohort, there was a negative correlation between glomerular fitration
rate and plasma homocysteine levels, suggesting that plasma homocysteine levels
are determined to a great extent by glomerular filtration. Recent interventional
trials have shown that lowering plasma homocysteine by means of vitamin sup-
pletion does not result in reduction of cardiovascular disease.
Atrial natriuretic peptide Administration of atrial natriuretic peptide (ANP) in-
creases albuminuria by increasing glomerular pressure by vasodilation of the af-
ferent glomerular arteriole. In our earlier experiments, the rise in albuminuria was
accompanied by an increase in the urinary excretion of the low-molecular weight
protein β2-microglobulin. This led us to hypothesize that ANP might increase
urinary albumin excretion not only by increasing glomerular pressure but also
by attenuating tubular protein reabsorption. However, in chapters 5 and 6 we
show that the abovementioned increase in low molecular weight proteinuria, after
administration of ANP, is not the consequence of ANP itself, but of polygelines
(Haemaccel®), the solvent used to prevent adherence of ANP to the infusion
system. We found that even low dosages of Haemaccel® were able to block
tubular reabsorption of low molecular weight proteins. The reabsorption of β2-
microglobulin is mediated by the megalin-cubulin complex, the system also used
for tubular reabsorption of tubulo-toxic medication like aminoglycosides. Possi-
bly, blockade of the megalin-cubulin complex by means of administration of low
dosages of polygelines can result in increased therapeutic application of aminogly-
cosides, when administered together. Interestingly, the megalin-cubulin complex
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is also found in the inner ear, possibly explaining the occurrence of ototoxicity
of aminoglycosides. Therapeutic application of polygelines for the prevention of
aminoglycoside-induced ototoxicity and renal tubular toxicity has not been per-
formed. This needs further investigation.
Endothelial function Endothelial dysfunction is thought to play an important role
in the developent of hypertension and atherosclerosis. Nitric oxide (NO), formerly
known as endothelial derived relaxation factor, plays an important role in arte-
riolar vasodilation. Alterations in NO-synthase activity could lead to decreased
vasodilation and hypertension. Chapter 7 describes the role of the Glu298Asp-
polymorphism of the NO-synthase gene on basal NO production. The Asp-allele
of the Glu298Asp-polymorphism is associated with reduced NO-production. Al-
though marked differences in basal NO production were observed between the
genotypes, no differences in basal forearm blood flow was observed. Apparently,
other mechanisms compensate for the decreased basal NO production.
NG-monomethyl-L-arginine (L-NMMA) is widely used in venous occlusion
plethysmography studies to determine basal NO production. However, the op-
timal dose to maximally inhibit NO production was unknown. Chapter 8 de-
scribes the results of a dose-response study of L-NMMA infusion to determine the
L-NMMA dose that maximally reduces basal forearm blood flow. The maximal
inhibiting dose of L-NMMA was 0.8 mg·min−1·dL−1, a dose higher than most
commonly used. At higher dosages of L-NMMA a systemic effect cannot be ruled
out.
Follow-up results of the PROFID-study
After 13 years of follow up the cumulative incidence of diabetic nephropathy was
4% (6 out of 148 participants), while based on data from historical cohorts the
expected incidence was 25-40% (30-60 participants). The hypotheses formulated
at the beginning of the prospective study could therefore not be tested. Why did
so few people develop diabetic nephropathy? Did we only include the patients
with good metabolic control? What went wrong with the inclusion?
To elucidate whether this lower incidence of diabetic nephropathy reflects a
change in the disease course of type 1 diabetes or is merely explained by selection
bias or poor follow-up, we compared the study population with eligible, non-
participating type 1 diabetes patients. The results of this evaluation are described
in chapter 9. The data show a similar incidence of diabetic nephropathy in the
PROFID-study population and in the eligible, type 1 diabetes patients who did
not participate. Both populations were comparable with regard to age at onset
of diabetes, gender, duration of diabetes at end of follow-up, and the percentage
of smokers. The reduced incidence of diabetic nephropathy therefore does not
reflect selection bias or poor follow-up, but suggests a real change in the disease
course of diabetic nephropathy.
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To investigate which factors might have contributed to this change in disease
course of diabetic nephropathy, a study of the total historic and current type 1
diabetes mellitus population of the outpatient clinic of the Radboud University
Medical Centre was carried out. Of the charts of 944 identified patients, 769 were
eligible for this study. Chapter 10 describes the results of this study. In type 1
diabetes mellitus the cumulative incidence of diabetic nephropathy has decreased
dramatically over the past decades. This improvement concurred with substan-
tially improved glycemic control and intensified treatment with antihypertensive
medication. Despite intensified treatement with antihypertensive medication, ac-
tual blood pressure levels remained virtually unchanged throughout the years. In
the population study as well as a case-control analysis, elevated blood pressure
levels are determinants for the development of diabetic nephropathy. Apparently
there is opportunity for intensifying antihypertensive treatment. Perhaps this
may lead to a further reduction of the incidence of diabetic nephropathy.
Conclusions
Over the years, the incidence of diabetic nephropathy has decreased dramatically.
The PROFID-study is not able to answer the question which factors determine
the development of diabetic nephropathy. From the population study we can
conclude that improved glycemic control is an important factor in the decreased
incidence of diabetic nephropathy. Although hypertension is an important factor
in the development and progression of diabetic nephropathy, the average blood
pressure remained virtually unchanged during the last decades despite intensi-
fied treatment. Apparently there is opportunity for intensifying antihypertensive
treatment. Perhaps this may lead to a further reduction of the incidence of dia-
betic nephropathy.
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Samenvatting
Niercomplicaties komen bij tot 40% van de mensen met type 1 diabetes mellitus
(suikerziekte) voor. In de Verenigde Staten is diabetische nefropathie zelfs de
belangrijkste reden voor het ondergaan van nierfunctievervangende behandeling
(hemodialyse, peritoneaaldialyse). Eerdere onderzoeken hebben aangetoond dat
goede instelling van de diabetes (metabole controle) het optreden van complicaties
kan voorkomen of in ieder geval uitstellen. Niet alleen een goede instelling van de
diabetes maar ook goede bloeddrukbehandeling kan het optreden van niercompli-
caties voorkomen.
Er zijn echter vele patie¨nten die ondanks een goede metabole controle en goede
behandeling van de bloeddruk toch niercomplicaties ontwikkelen. Ook zijn er
patie¨nten die geen niercomplicaties krijgen ondanks matige instelling van de dia-
betes en slechte regulatie van de bloeddruk: andere factoren dan diabetesinstelling
en bloeddrukbehandeling alleen moeten een rol spelen.
In de onderzoeken beschreven in dit proefschrift probeerden we de vraag te
beantwoorden, welke factoren, naast bloedsuikerregulatie en bloeddruk, een rol
spelen bij de ontwikkeling van niercomplicaties (diabetische nefropathie) bij type
1 diabetes mellitus.
Dankzij een subsidie van het Diabetesfonds Nederland, is hiertoe in 1994 een
onderzoek gestart, waarbij honderdachtenveertig mensen met type 1 diabetes mel-
litus, zonder niercomplicaties, gedurende lange tijd (tot 13 jaar) gevolgd werden
op de ontwikkeling van niercomplicaties. De studie heeft het acroniem PROFID-
studie mee gekregen (PROgnostic Factors In Diabetic nephropathy). Bij deze
mensen werd bij aanvang van het onderzoek een grote serie onderzoeken uitge-
voerd, waarna deze deelnemers gedurende lange tijd gevolgd werden op de ont-
wikkeling van niercomplicaties. Aan het einde van het onderzoek zou nagekeken
worden waarin de deelnemers die wel complicaties zouden ontwikkelen zouden
verschillen van de deelnemers die na al die jaren geen complicaties ontwikkeld
zouden hebben.
Bij aanvang van het onderzoek ondergingen de deelnemers een uitvoerige serie
onderzoeken in een poging de volgende vraagstellingen te beantwoorden:
1. Kan de ontwikkeing van nierschade worden voorspeld door het meten van ve-
randeringen in de nierdoorbloeding en de albumine-uitscheiding in de urine
na toediening van atriaal natriuretisch peptide (ANP)? Hiertoe ondergingen
de deelnemers een invasieve nierfunctiemeting. Voor en na toediening van
ANP werden filtratie, nierdoorbloeding en albuminerie gemeten.
2. Kan de ontwikkeling van nierschade worden voorspeld door het meten van
de endotheelfunctie? De endotheelfunctie werd gemeten aan de hand van ve-
randeringen in de doorbloeding van de onderarm tijdens infusie van diverse
geneesmiddelen in de slagader van de onderarm.
3. Kan de ontwikkeling van nierschade worden voorspeld door het meten van
de activiteit van het natrium-lithium countertransport, welke mogelijk een
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maat is voor erfelijke hoge bloeddruk? Hoge bloeddruk (hypertensie) blijkt
vaak familiair voor te komen. Toegenomen Na-Li-countertransport is geas-
socieerd met hypertensie. Mogelijk dat een toegenomen activiteit van het
Na-Li-countertransport in de erythrocyt (rode bloedcel) een vroege voor-
speller is voor het krijgen van verhoogde bloeddruk.
4. Kan de ontwikkeling van nierschade voorspeld worden door het kwantifi-
ceren van heparansulfaat-proteoglycanen in serum en urine? Heparansulfaat-
proteoglycanen spelen een belangrijke rol bij de ladingsafhankelijke door-
laatbaarheid van basaalmembranen, niet alleen in het nierfilter (glomeru-
lus) maar ook in de vaatwand. (Veel) urine en bloed werd verzameld om dit
nader te onderzoeken.
In hoofdstuk 2 wordt een overzicht gegeven van de factoren die bijdragen aan
de ontwikkeling van diabetische nefropathie. Zowel metabole als hemodynamische
veranderingen spelen een rol.
Vaatverwijding speelt mogelijk een belangrijke rol in de ontwikkeling van nier-
complicaties, omdat het aanleiding kan geven tot verhoogde druk in het micro-
scopische vaatbed. Dit kan aanleiding geven tot een toegenomen lekkage van
eiwit door de vaatwand. Inderdaad kan bij patie¨nten met type 1 diabetes melli-
tus (vaak) een toegenomen nierdoorbloeding worden vastgesteld. De oorzaak van
deze toegenomen doorbloeding is onbekend. De toegenomen glomerulaire filtratie
wordt toegeschreven aan een vaatverwijding voor het nierfilter (glomerulus). Dit
leidt tot een toegenomen filtratie door het filter. Recent is echter de hypothese
geopperd dat een verhoogde tubulaire natriumreabsorptie aanleiding geeft tot
toegenomen glomerulaire filtratie. Hoofdstuk 3 beschrijft een mogelijke verklar-
ing voor de toegenomen filtratie bij mensen met type 1 diabetes mellitus. Wij
vonden aanwijzigen dat de toegenomen natriumreabsorptie leidt tot een toename
van de nierdoorbloeding door activering van de tubulo-glomerulaire feedback. De
toegenomen glomeruaire filtratie lijkt niet het gevolg te zijn van een systemische
volumetoename of van een verhoogd atriaal natriuretisch peptide.
Van homocysteine is lange tijd gedacht dat het bijdraagt aan aderverkalking
en dat het een onafhankelijke risicofactor is voor het krijgen van hart- en vaatziek-
ten. Ondanks dat type 1 diabetes mellitus ook gepaard gaat met een toegenomen
incidentie van hart- en vaatziekten, blijkt bij mensen met type 1 diabetes melli-
tus de homocysteine-spiegel juist verlaagd. Hoofdstuk 4 beschrijft dat het lagere
homocysteine-gehalte een gevolg is van de toegenomen nierfiltratie.
Voorheen werd er vanuit gegaan dat de primaire functie van ANP het veroorza-
ken van drukverhoging in het nierfilter was. ANP doet dit door het veroorzaken
van vaatverwijding voor het filter en vaatvernauwing na het filter. In onze eerste
studies werd echter aangetoond dat toediening van ANP leidde tot een vermin-
derde opname van eiwit in de niertubuli. In hoofdstuk 5 en 6 wordt beschreven
dat dit niet het gevolg is van ANP, maar van het gebruikte middel waarin ANP
werd opgelost (Haemaccel). Haemaccel blijk dus de tubulaire opname van stoffen,
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zoals kleine eiwitten, te blokkeren. Dit zou zowel therapeutische als diagnostische
doelen kunnen dienen.
Endotheeldysfunctie lijkt een belangrijke rol te spelen in de ontwikkelling
van hypertensie en atherosclerose. Hoofdstuk 7 beschrijft de rol van een gene-
tische variant van het stikstofmonoxide-synthetase (NO-synthase). Het blijkt dat
mensen met een of meer Asp-allellen van het Glu298Asp-polymorfisme van het
NO-synthasegen een verminderde basale NO-productie hebben. Toekomstig on-
derzoek moet uitwijzen of deze mensen ook een verhoogde kans hebben op het
optreden van hypertensie of atherosclerose.
In eerdere studies is vaak gebruik gemaakt van NG-monomethyl-L-arginine
(L-NMMA) om de basale stikstofoxide (NO) productie, hetgeen vaatverwijding
veroorzaakt, te meten. Hiertoe is in vele onderzoeken gebruik gemaakt van het
toedienen van opklimmende doseringen L-NMMA. Ook in de PROFID-studie werd
L-NMMA gebruikt omde basale NO-productie te meten. De dosering waarbij de
maximale blokkade van NO-productie plaatsvindt was echter onbekend. Hoofd-
stuk 8 beschrijft het onderzoek naar de dosis welke de maximale blokkade geeft
van NO-productie. Hieruit blijkt dat alle tot dan toe uitgevoerde studies een te
lage dosering L-NMMA hebben gebruikt. Wat verder opvalt is dat bij hogere
doseringen een systemisch effect van L-NMMA niet kan worden uitgesloten.
Bij aanvang van de studie werd op grond van historische gegevens verwacht dat
ongeveer 25-40 % van de deelnemers nefropathie zou ontwikkelen. De PROFID-
studie heeft van 1994 tot 2007 gelopen. Gedurende die periode hebben zes mensen
diabetische nefropathie ontwikkeld terwijl verwacht werd dat tussen de 30 en 60
deelnemers nefropathie zouden ontwikkelen. Hierdoor kunnen de uitgangsvragen
vooralsnog niet worden beantwoord. Het is dus de vraag wat de oorzaak is van
dit veel lagere aantal mensen met nefropathie in vergelijking met de historische
gegevens. Hebben we alleen de mensen met een goede instelling weten in te
sluiten in het onderzoek? Is er een probleem met de follow-up? Is het onderzoek
nu mislukt?
Hoofdstuk 9 beschrijft een populatie-onderzoek waarbij de deelnemers aan de
PROFID-studie worden vergeleken met mensen met type 1 diabetes mellitus die
wel met het onderzoek mee konden doen, maar desondanks niet met het onderzoek
hebben mee gedaan. Het blijkt dat beide groepen (deelnemers en niet-deelnemers)
volledig vergelijkbaar waren ten aanzien van aantal mensen dat nefropathie heeft
ontwikkeld, bloedsuikerregulatie, bloeddrukregulatie en rookgedrag. Ook was er
geen verschil in sexe-verdeling. Het lijkt er dus op dat de deelnemers een goede
representatie zijn van de populatie in zijn geheel. Daarnaast blijkt er sprake te
zijn van een veel minder voorkomen van nefropathie dan in historische populaties
beschreven is. Het in de onderzoekspopulatie waargenomen lage aantal compli-
caties lijkt dus ree¨el.
Om te onderzoeken welke factoren het verminderd optreden van nefropathie
verklaren werden alle data geanalyseerd van alle bekende type 1 diabetes-patie¨nten
in het UMC St Radboud. Wanneer deze patie¨ntengroep opgedeeld wordt in
groepen naar jaar van ontstaan van de diabetes mellitus, dan blijkt er over de
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jaren inderdaad een significante daling van het aantal gevallen van nefropathie
te zijn. Verder valt op dat over de jaren de bloedsuikerinstelling sterk verbeterd
is. Opmerkelijk genoeg blijkt de gemiddelde bloeddruk over de jaren nagenoeg
onveranderd te zijn. Wel worden patie¨nten vaker behandeld met bloeddrukverla-
gende medicijnen. Deze populatie is ook nog op een andere manier geanalyseerd:
voor iedere patie¨nt die nefropathie ontwikkeld heeft (Case), is er een gematchte
patie¨nt, zonder nefropathie, bijgezocht (Controle). Wanneer beide groepen met
elkaar vergeleken worden, dan blijkt dat de cases een slechtere bloedsuikerreg-
ulatie te hebben dan de controles. De bloeddrukwaarden van de cases bleek
hoger te zijn dan die van controles. Ook werden cases vaker behandeld met
bloeddrukverlagende medicatie. Uit een multi-variate analyse blijkt dat bloed-
suikerregulatie en het krijgen van bloeddrukverlagende medicatie de belangrijkste
voorspellers zijn voor de ontwikkeling van diabetische nefropathie. Deze resul-
taten staan beschreven in hoofdstuk 10.
Conclusie
Over de jaren is het aantal mensen met type 1 diabetes mellitus dat nefropathie
ontwikkelt, aanzienlijk gedaald. De PROFID-studie kan geen uitspraak doen over
de mogelijke oorzaken van diabetische nefropathie. Uit het populatie-onderzoek
blijkt dat betere bloedsuikerregulatie een belangrijke oorzaak is van de afname in
de incidentie van diabetische nefropathie. Hoewel een verhoogde bloeddruk bij-
draagt aan het ontstaan van diabetische nefropathie, is de gemiddelde bloeddruk
de afgelopen jaren niet gedaald. Door betere behandeling van verhoogde bloed-
druk kan het aantal gevallen van diabetische nefropathie mogelijk nog verder
afnemen.
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Dankwoord
Er staat slechts e´e´n naam voor op dit proefschrift. Het is echter tot stand gekomen
door de bewuste, maar vaak ook onbewuste medewerking en steun van velen. Zon-
der iemand te kort te doen wil ik enkelen noemen. Uitputtend kan de opsomming
niet zijn. Te veel mensen hebben bijgedragen: Honderden, nee, de meer dan
duizend patie¨nten die hebben bijgedragen aan de totstandkoming van dit proef-
schrift. Velen hebben kostbare tijd ge¨ınvesteerd in de resultaten zoals beschreven
in het proefschrift. Het aantal infusen dat zij hebben gekregen, de hoeveelheid
bloed en urine dat van hen is nagekeken, gaat de verbeelding te boven. De per-
soonlijke contacten tijdens de vaak langdurige metingen waren altijd weer inter-
essant.
Prof. Dr. J.H.M. Berden (beste Jo), Prof. Dr. P. Smits (beste Paul), Prof.
Dr. J.F.M. Wetzels (beste Jack) en Dr. G. Vervoort (beste Gerald). Het is
een voorrecht om met zo’n aangenaam gezelschap met zo ongelofelijk veel kennis,
inzicht en ervaring te mogen samenwerken. Soms voelde het voor mij als of het
project wat ‘top-zwaar’ was, dat het project meer kanten uit ging dat een enkele
promovendus kon behappen. De vruchtbare gezamelijke overlegmomenten, die
trouwens niet of nauwelijks te plannen waren, wisten het onderzoek altijd weer
richting te geven. Bedankt voor jullie vertrouwen.
Aarnout Jansen van Rosendaal en Eugenie Olde Riekerink-Weijermans, jullie zijn
van onschatbare waarde voor dit onderzoek geweest. Heel veel metingen hebben
jullie zo door de jaren heen gedaan. Jullie flexibiliteit, inventiviteit maar zeker
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ook gezellige babbels op de klinische fysiologie hebben de onderzoekstijd tot een
mooie gemaakt. Hans Schepkens gaf het onderzoek een zuidelijk, internationaal
karakter. Marloes, je hebt me ingehaald.
Patie¨nten motiveren voor deelname aan wetenschappelijk onderzoek is niet een-
voudig. Vooral wanneer je mensen zoekt in de bloei van hun leven, hen con-
fronteert met “ziek zijn” terwijl ze zich vaak goed voelen, hen onderwerpt aan
langdurige, toch belastende studies. De Diabetesgroep (o.a. Jos Lutterman, Cees
Tack, Lammy Elving, Bernadet Cools, Petra van Gurp, Frank Huvers en de dia-
betesverpleegkundigen) en de geaffilieerde ziekenhuizen (Paetrick Netten: Jeroen
Bosch Ziekenhuis, Rudi van Doorn: Twee Stedenziekenhuis Tilburg, Bert Braven-
boer: Catharina Ziekenhuis Eindhoven) zijn hier goed in geslaagd.
Prof. Dr. Jos van der Meer. Als voorvechter van de AGIKO-constructie heb
je dit grandioze project mogelijk gemaakt. Jos, bedankt!
De vele collegas van de afdeling Algemeen Interne Geneeskunde en Nierziek-
ten, zowel tijdens opleiding, als onderzoek hebben het leven zeker aangenamer
gemaakt.
De mensen van de diverse laboratoria, met name het ‘CKCL’ (thans AKC). In
het bijzonder Coby Laarakkers, Annemarie Hovingh en Ronald van Vliet, Joop
Goe¨rtz, Stan Verwij, Ina Klaassen en Prof. Dr. Hans Willems: bedankt voor
de goede, aangename samenwerking. Het lab kindergeneeskunde: m.n. Henk
Blom: inspirerend, snel, laagdrempelig, erg aangenaam. Afdeling Nucleaire Ge-
neeskunde: m.n. Wim van den Broek. Maastricht, tegenwoordig Utrecht: Wilko
Spiering. De mensen van moleculaire biologie op de faculteit Wis- Natuurkunde:
Maldi-TOF is het moderne piskijken! GLIMS-databeheer (in het bijzonder Gerard
Dulos) voor het snel en zorgvuldig aanleveren van de gigantische hoeveelheid data.
De collega’s van de maatschap interne geneeskunde / maag-darm-leverziekten
van het Canisius Wilhelmina Ziekenhuis te Nijmegen, in het bijzonder de collega
nefrologen (Marc ten Dam en Rik ter Meulen) voor het mogelijk maken van de
afronding van het proefschrift.
Het Diabetesfonds Nederland, voor het verstrekken van de subsidie die dit on-
derzoek mogelijk heeft gemaakt.
Alle vrienden en familie. Bedankt voor alle steun, afleiding, en gezelligheid. Laten
we vooral zo doorgaan.
Mijn ouders, die me hebben laten worden wat ik geworden ben. Bedankt voor
jullie steun!
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Nynke, Mendel en Carlijn, doorploeteren tot in de kleine uurtjes is er nu wel
vanaf, en dat is maar goed ook.
Ingeborg, mijn rots in de branding: later is nu (echt?) begonnen.
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trum St. Radboud te Nijmegen (opleider Prof. Dr. J.W.M. van der Meer). De
opleiding werd gecombineerd met promotieonderzoek naar prognostische factoren
voor de ontwikkeling van diabetische nefropathie bij mensen met type 1 diabetes
mellitus (Projectsubsidie van het Diabetesfonds; 92.602). Van 2004 tot mei 2005
vond de opleiding tot internist plaats in het Canisius Wilhelmina Ziekenhuis te
Nijmegen (Opleider Dr. A.S.M. Dofferhoff).
De opleiding tot internist werd op 1 januari 2007 afgerond. Hierna volgde
de opleiding in het aandachtsgebied Nefrologie, gedeeltelijk in het Universitair
Medisch Centrum St. Radboud (Opleider Prof. Dr. J.H.M. Berden), gedeeltelijk
in het Canisius Wilhelmina Ziekenhuis (Opleider Dr. M. ten Dam). Sinds 1 maart
2008 is hij werkzaam als internist-nefroloog in het Canisius Wilhemina Ziekenhuis
te Nijmegen.
Hij is getrouwd met Ingeborg de Jonge. Samen hebben ze drie kinderen:
Nynke (2002), Mendel (2004) en Carlijn (2008).
i
i
“thesis” — 2009/9/17 — 20:34 — page 134 — #140 i
i
i
i
i
i
i
i
“thesis” — 2009/9/17 — 20:34 — page 135 — #141 i
i
i
i
i
i
i
i
“thesis” — 2009/9/17 — 20:34 — page 136 — #142 i
i
i
i
i
i
i
i
“thesis” — 2009/9/17 — 20:34 — page 137 — #143 i
i
i
i
i
i
i
i
“thesis” — 2009/9/17 — 20:34 — page 138 — #144 i
i
i
i
i
i
